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The classical tachykinin substance P (SP) has numerous potent neuroimmunomodulatory 
effects in many inflammatory diseases. Belonging to a class of neuro-mediators targeting 
not only residential cells but also inflammatory cells, studying SP provides important 
information on the bidirectional linkage between how neural function affects 
inflammatory events and in turn, how inflammatory responses alter neural activity.  
 
Burn injuries are one of the most common and devastating forms of trauma. One of the 
major causes of mortality in burn patients is respiratory failure, due to the development of 
acute lung injury (ALI), even without direct inhalational injury. Hence, much research 
interest is focused on understanding the role of mediators that contribute to the 
pathophysiology of burn-induced ALI. However, the role of SP in inducing inflammation 
in the lungs after burn injury is not known. Therefore, this study aimed to investigate 
whether SP instigates distant pulmonary SP release and ALI after severe local burn injury.  
 
A 30% total body surface area full-thickness burn induced in male Balb/c wild-type (WT) 
mice showed heightened pulmonary SP production and SP-neurokinin-1-receptor 
(NK1R) signaling, a G protein coupled receptor, which SP binds preferentially to. 
Concurrently, elevated pro-inflammatory cytokines, chemokines, neutrophil infiltration, 
and increased microvascular permeability were observed. Furthermore, histological 
examination reveals higher alveolar congestion, interstitial inflammatory cellular 
 xii 
infiltrates and edema, all of which are evidences of severe ALI. Notably, these effects 
were abolished in burn-injured WT mice pre-treated with L703606, a specific NK1R 
antagonist, and in burn-injured preprotachykinin-A (PPT-A) gene deficient mice, which 
encodes for SP; while exogenous administration of SP to burn-injured PPT-A
-/- 
mice 
restored the inflammatory response and ALI.  
 
Results of the present study provide for the first time compelling evidence, that the 
enhanced release of SP levels in lung and blood could be a critical factor leading to the 
pathophysiology of remote ALI and disruption of breathing function early after severe 
local burn injury. Taken together, with an in-depth understanding of the early pro-
inflammatory effects of SP, new approaches maybe achieved for the prevention of an 
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Chapter I   Introduction 
 
 
1.1 General overview 
 
 
Communication between the nervous system and the process of inflammation are 
interwoven. The intricate networks of the nervous system made up of the brain and its 
central and peripheral divisions can set off or impede activities of the innate immune 
system that is directly involved in inflammatory responses. Likewise, cells of the immune 
system, through the secretion of signaling messengers such as cytokines, can influence 
activities of the nervous system (Nguyen et al., 1996; Steinman, 2004; Tracey et al., 
1986). Thereby, it is critical to understand the messengers involved in such mechanisms 
of cross talk between major systems. One such key link is the neuropeptide connection.  
 
The nervous system has a number of characteristics that make it a perfect partner with the 
innate immune system in coordinating immediate inflammatory responses to injury or 
pathogens. It reacts right away, in a matter of milliseconds to minutes, to numerous non-
specific insults (Sternberg, 2006). Neurotransmitters and neuropeptides, released by 
nerve cells, typically activate the same signaling transduction pathways as those activated 
by immune mediators via binding to G-protein-coupled receptors which result in 
stimulation of cyclic AMPs and protein kinases such as mitogen-activated protein kinases 
(Sternberg, 2006). Furthermore, neuropeptides, particularly, the well-known classical 
tachykinin, substance P (SP), stimulates the production of pro-inflammatory mediators 
such as histamine that contribute to inflammatory responses. While in-turn, numerous 
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immune mediators express or interact with receptors of neuropeptides and 
neurotransmitters, thereby regulating neural activities that are fundamental to the acute 
phase response (Grimm et al., 1998; Milligan et al., 2005; Watkins and Maier, 1999). 
Taken together, these characteristics of the nervous system, specifically, the peripheral 
nervous system, position it to provide a first line of defense at sites of injury via the 
secretion of neuropeptides that generally elevate inflammatory responses (Sternberg, 
2006).   
 
Burn-induced acute lung injury is a common clinical disorder associated with high 
morbidity and mortality in medical and surgical intensive care units (Dancey et al., 1999). 
The primary etiological factor of death after severe burns is multiple organ failure with 
the lungs often being the first organ to fail (Turnage et al., 2002). Once respiratory failure 
occurs, therapeutic interventions are limited (Wheeler and Bernard, 2007). Therefore, 
intense research on elucidating mechanisms of burn induced pulmonary pathophysiology 
and potential preventive strategies are of great interest.  
 
Even in the absence of inhalational injury, the ongoing local burn wound inflammation is 
the triggering source of systemic inflammatory response and multiple organ failure 
(Arturson, 1996; Bone, 1992). The underlying mechanism is thought to be a network 
combination of burn-induced liberation of inflammatory mediators, such as cytokines, 
chemokines, complement factors, leukocytes and neutrophil trafficking (Arturson, 1996). 
However, the exact role of neuropeptides, such as SP, in regulating acute lung injury after 
severe burns still remains unknown. Therefore, in the present study, we have investigated 
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the potential role of SP in instigating remote acute lung injury in a mouse model of severe 
local burns. Additionally, we have explored the molecular mechanisms by which SP 
would modulate the inflammatory responses in lungs after burn.  
  
1.2 Substance P (SP) 
 
 
1.2.1 Physical properties, sources, distribution and biosynthesis of SP 
 
 
SP was discovered by von Euler and Gaddum as an 11 amino acid peptide, with a 
structure comprising of: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (Von 
Euler US and Gaddum JH, 1931). SP belongs to the tachykinin family of bioactive 
neuropeptides defined by their common carboxyl-terminal sequence Phe-X-Gly-Leu-
Met-NH2, where X is an aromatic (Tyr or Phe) or hydrophobic (Val or Ile) amino acid 
(Chang et al., 1971; Uddman R et al., 1997). This conserved sequence is essential for the 
tachykinin‟s binding and activation to its receptor. In mammals, five tachykinin peptides 
have been identified: SP, neurokinin-A and B, neuropeptide K and γ, all of which are 
encoded by the preprotachykinin-A (PPT-A) gene through alternative splicing (Nawa et 
al., 1984).  
 
SP is produced by both neuronal and non-neuronal sources. Neuronal sources represent 
the primary source of SP release by non-myelinated C-fiber sensory nociceptive neurons 
that respond to heat, cold, chemical or other noxious stimuli (O'Connor et al., 2004). 
Additionally, SP is also produced by numerous important immune cells (O'Connor et al., 
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2004) including neutrophils, macrophages, eosinophils, monocytes, lymphocytes, mast 
cells, dendritic cells and platelets (Graham et al., 2004). Its synthesis is widely distributed 
in the central and peripheral nervous systems and in all major organs forming the 
respiratory, gastrointestinal, musculoskeletal and cardiovascular systems (O'Connor et al., 
2004). Particularly, for the airways, non-myelinated C-fibers is the most abundant vagal 
afferents that innervate the lungs (Jia and Lee, 2007; Takemura et al., 2008). The afferent 
activity arising from C-fiber endings exerts an important influence in regulating airway 
functions under both normal and pathophysiological conditions.  
 
Biosynthesis of SP initially occurs as a larger protein in the ribosomes of neuronal cell 
bodies of the trigeminal, jugular and nodose ganglia. It is then packaged into storage 
vesicles and exported to the terminal endings of the central and peripheral branches of 
sensory neurons by a mechanism of axonal transport, where it is enzymatically converted 
to the undecapeptide and stored (Brimijoin et al., 1980; Harmar et al., 1980). 
Immunohistochemical and biochemical studies show that the accumulation of SP in the 
peripheral branches is four times greater compared to the dorsal root (Harmar et al., 
1980). Upon stimulation of C-fibers, a multi-modal, non-selective cation channel, known 
as the transient receptor potential vanilloid1 (TRPV1), which is predominantly found in 
sensory C-fibers are further activated and are responsible for the release of SP. This  
event initiates the onset of a phenomenon termed „neurogenic inflammation‟ which refers 
to the inflammatory responses that result from the release of molecules from primary 
sensory nerve fibers (Clapham, 2003). 
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1.2.2 Neurokinin-1 receptor 
 
The biological actions of SP are mediated by neurokinin receptors, which belong to a 
family of ubiquitous G protein-coupled receptors, comprising of neurokinin-1 receptor 
(NK1R), NK2R and NK3R. Of these three receptors, the membrane bound NK1R has the 
highest affinity for SP. The relative affinity of NK1R for SP is 500 and 100 folds higher 
than its affinity for neurokinin-A and B (Elling et al., 1995; Gerard et al., 1991; Holst et 
al., 2001; Macdonald et al., 1996). The distribution of NK1R is found in all major organs 
of the body including the lungs (O'Connor et al., 2004), and has been shown to be 
expressed in numerous immune cells including neutrophils (Iwamoto et al., 1993), 
eosinophils (Iwamoto et al., 1993), lymphocytes (Guo et al., 2002), monocytes (Ho et al., 
1997), macrophages (Ho et al., 1997) and mast cells (Ansel et al., 1993).    
 
1.2.3 Neural-immune bi-directional communication 
 
The same neuropeptides produced in the nervous system is also produced in the immune 
system. Release of neuropeptides was thought to be facilitated via anterograde and 
retrograde peptide transport since the primary and secondary lymphoid organs are well-
innervated (Rameshwar, 1997). However, studies reported molecular mechanisms by 
which the nervous and immune systems communicate in order to address specific 
questions, the rationale being the synthesis of neuropeptides and expression of their 
receptors on resident cells and cells within lymphoid organs, which result in functional 
responses when activated (Kavelaars et al., 1994; O'Connor et al., 2004; Payan and 
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Goetzl, 1985; Savino and Dardenne, 1995). Thereby, rendering continual transportation 
of neuropeptides from a distant neural source unnecessary and hence raising questions of 
the extent and kinetics of anterograde and retrograde transports. This phenomenon of 
inter-system crosstalk between the nervous and immune system is termed the neuro-
immune axis and is mediated via a common biochemical language of shared molecules 
involving mainly neuropeptides such as SP, cytokines, and their receptors (Brogden et al., 
2005; Steinman, 2004; Sternberg, 2006). Peptidergic mechanisms and inflammatory 
mediators earlier thought to occur and be secreted solely by the nervous system are now 
known to also be synthesized by immune cells, and vice versa. Thereby, enabling a 
widespread network of complex communication between peptidergic nerves and 
immunocytes present in all organs of the body, including the respiratory system.  
 
1.2.4 Pro-inflammatory effects of SP 
 
SP serves as one of the major mediators in neuro-immune interactions. Activation of the 
SP-NK1 receptor complex produces a variety of neuro-immune responses in mammalian 
airways including increased microvascular permeability and plasma extravasation, 
immune cell influx, increased edema, vasodilation and glandular secretions, thereby 
contributing to heightened inflammation (Groneberg et al., 2006; O'Connor et al., 2004). 
SP also stimulates lymphocyte proliferation and immunoglobin production, elicits 
activation of pro-inflammatory transcription factors and activates inflammatory cells such 
as neutrophils, lymphocytes, monocytes, macrophages and mast cells to produce 
cytokines, oxygen free radicals, arachidonic acid derivatives and histamine, all of which 
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exacerbate tissue injury, amplifying the inflammatory response in many inflammatory 
diseases of the respiratory, gastrointestinal,
 
and musculoskeletal systems (Groneberg et 
al., 2006; Groneberg et al., 2004; O'Connor et al., 2004).  
 
The diverse availability of SP and NK1R expression in the body positions SP to influence 
many physiological and pathological conditions. Its effects are evidently pro-
inflammatory and hence plays a critical role in a variety of immune and inflammatory 
disorders, including polymicrobial sepsis (Puneet et al., 2006), asthma (Van Rensen et al., 
2002), endotoxemia (Takemura et al., 2008), inflammatory bowel disease (Koon et al., 
2006), acute pancreatitis (Bhatia et al., 1998a; Bhatia et al., 2003) and rheumatoid 
arthritis (Grimsholm et al., 2007). Therefore, it is obvious that an extensive cross-talk 
exists between SP and the inflammatory response to injury.   
 
1.2.5 SP and immunoregulation   
 
SP exerts a diverse spectrum of immunoregulatory effects on numerous immuno-
inflammatory cells by intricately interacting with them (Zhang and Dong, 2005). An 
inflammatory response is initiated by invasion of polymorphonuclear leukocytes 
followed by recruitment of macrophages and T-cells to the injured site. The process of 
launching an inflammatory response relies on a tightly regulated multi-step signaling 
cascade typically involving neutrophils, macrophages, monocytes, eosinophils, mast cells, 
lymphocytes, dendritic cells, adhesion molecules, eicosanoids and an intricate network of 
cytokines, all of which SP has been implicated to be involved in,                             
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leading to the pathophysiology of a variety of acute and chronic inflammatory diseases 
(O'Connor et al., 2004).  
 
1.2.5.1 SP and immunoregulation: neutrophils  
 
 
SP significantly enhances the migratory and cytotoxic functions of neutrophils. Studies 
show that SP can specifically stimulate the chemotaxis of neutrophils and induce the 
expression of the leukocyte integrin CD11b on human neutrophils (O'Connor et al., 2004). 
SP induces increases in the adherence of neutrophils to lung epithelial cells in vivo, 
induces the degranulation of human neutrophils, stimulates neutrophil respiratory burst, 
hydrogen peroxide production and secretion of granular constituents (DeRose et al., 
1994; Kuo et al., 2000; Serra et al., 1988). The augmented adherence of neutrophils to 
epithelial cells is mediated by NK1R, present on the surface of neutrophils and is due to 
the effects of the C terminus in SP (O'Connor et al., 2004).    
 
1.2.5.2 SP and immunoregulation: cytokines  
 
 
SP induces the production of IL-1, IL-6, and TNF-α in monocytes, macrophages (Ho et 
al., 1996; Lotz et al., 1988) and in lung cells (Veronesi et al., 1999); IL-2, IL-6, IL-1β, 
and TNF-α release in neutrophils (Delgado et al., 2003); IL-2 in human T cells (Calvo et 
al., 1992); IL-3 and granulocyte macrophage-colony stimulating factor (GM-CSF) in 
bone marrow mononuclear cells (Rameshwar et al., 1994); IFN-γ in peripheral blood 
mononuclear cells (Wagner et al., 1987); and CD117 or c-kit and IL-7 in bone marrow 
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stromal cells (Manske et al., 1995). The same cytokines which are up-regulated by SP 
can also induce NK1R expression and regulation by these cytokines may occur in an 
autocrine and paracrine manner. For example, SP stimulates IL-1 and stem cell factor in 
bone marrow stroma of mice, while these cytokines in turn modulate stromal expression 
of NK1R (Rameshwar and Gascon, 1995). This shows that the cytokines and SP can 
induce the synthesis of each other, suggesting that non-neuronal sources play an 
important role in an acute inflammatory response.  
 
1.2.5.3 SP and immunoregulation: lung epithelium 
 
 
In the human respiratory tract, an extensive and continuous pathway of SP-immuno-
reactive sensory nerves are located throughout the epithelium to arterioles in bronchial 
mucosa, around submucosal bronchial glands and blood vessels, providing structural 
support for a local axon reflex. Significant levels of SP are found in central and 
peripheral airway tissues, bronchoalveolar lavage fluid and sputum.    
 
1.2.6 SP in respiratory tract diseases  
 
 
Numerous clinical and animal studies have implicated SP to exert numerous pro-
inflammatory effects in airway diseases (Groneberg et al., 2006). Induction of PPT-A 
gene expression and SP levels are up-regulated significantly in airway neurons during 
allergic airway inflammation, asthma and chronic bronchitis (Harrison and Geppetti, 
2001; O'Connor et al., 2004). In the airways, prominent extravascular neurogenic 
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inflammatory effects include significant bronchoconstriction, vasodilation, oedema 
formation, mucus hypersecretion, inflammatory cell chemotaxis and stimulation and 
release of inflammatory mediators including prostaglandins and nitric oxide (Groneberg 
et al., 2006).   
 
Asthmatic patients showed increased SP levels in bronchoalveolar lavage fluid and 
sputum (Tomaki et al., 1995). Further evidence from autopsy (Ollerenshaw et al., 1991), 
lobectomy (Lilly et al., 1995) and bronchoscopy (Tomaki et al., 1995) samples implicated 
SP to be involved in the development of bronchial hyperresponsiveness in asthmatic 
patients. The amount of SP detected in non-asthmatics was significantly lower than 
asthmatics, while expression of NK1R levels was likewise lower in non-asthmatics 
compared to asthmatics (Adcock et al., 1993; Howarth et al., 1991). Animal studies 
showed that administration of NK1R antagonist (Ichinose et al., 1992; Solway et al., 
1993) induced abrogated bronchial hyperreactivity and plasma leakage compared to 
animal models induced with asthma. Ovalbumin-sensitized and challenged guinea pigs 
had evidence of increased SP (Fischer et al., 1996) and bronchoconstriction produced by 
NK1R activation (Bertrand et al., 1993); while mice deficient in NK1R showed abolished 
lung injury and neutrophil infiltration compared to mice induced with airway allergy 
(Bozic et al., 1996). Cigarette smoking exposure induces SP release from sensory nerves 
along with airway hyperresponsiveness and cough, adhesion of leukocytes to tracheal 
mucosa and increased neurogenic inflammatory responses (Baluk et al., 1996; Dusser et 
al., 1989; Kwong et al., 2001; Lundberg and Saria, 1983). Guinea pigs exposed to 
tobacco smoke demonstrated an early phase of bronchoconstriction induced by 
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cholinergic reflex and SP release and a late phase caused by arachodonic acid metabolites, 
which SP has been shown to stimulate (Hong and Lee, 1996). Increased SP and NK1R 
levels were also found in BALF of patients with idiopathic pulmonary fibrosis and 
sarcoidosis (Takeyama et al., 1996). Airway rapidly adapting afferent nerves were shown 
to be involved in cough reflex. In normal subjects, no SP is present in these nerves, 
however, upon induction of allergic inflammation and viral infection, the nerves start to 
produce SP (Carr et al., 2002; Hunter et al., 2000). Patients displaying non-asthmatic 
chronic cough have elevated SP levels, IL-8 and neutrophilia (Pizzichini et al., 1999). 
Nasal allergic reactions also results in SP release and plasma leakage in the nose of 
patients with allergic rhinitis (Braunstein et al., 1991).    
 
1.2.7 Metabolism of SP 
 
 
The biological actions of SP is terminated by mainly two enzymes: neutral endopeptidase 
(NEP) and angiotensin converting enzyme (ACE) (Di Maria et al., 1998). However, NEP 
is abundantly expressed in the airways and has been shown to be more important than 
ACE in degrading SP in the lungs (Martins et al., 1991). NEP is a cell surface enzyme, 
located in the nerves, epithelium, smooth muscles, and glands of the respiratory trachea, 
where it is ideal to degrade SP upon released from sensory nerves and where SP acts. 
Following inactivation of SP by proteolysis, the fragments are cleared by peptide 
transporters which are expressed throughout the airways (Groneberg et al., 2002; 
Groneberg et al., 2001). NEP activity has been shown to significantly affect SP 
responsiveness in the lungs. Inhibition of NEP potentiates airway smooth muscle 
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contraction, plasma extravasation and airway mast cell activation (Nadel and Borson, 
1991; Roques et al., 1993). Targeted deletion of NEP expression in mice by disruption of 
the NEP gene resulted in augmented inflammation, greater susceptibility to septic shock, 
hypotension and widespread plasma leakage from postcapillary venules that is mediated 
by NK1R activation (Lu et al., 1997; Lu et al., 1995; Sturiale et al., 1999). Studies have 
also demonstrated that stimuli such as cigarette smoke, hypochlorous acid, toluene 
diisocyanate and viral infections such as influenza virus A/Taiwan, the Sendai virus and 
Mycoplasma decrease NEP activity, amplifying the neurogenic inflammatory response to 
SP (Borson, 1991; Di Maria et al., 1998; Nadel, 1991).      
 
1.2.8 SP signaling pathways 
 
 
Binding of SP to its high affinity NK1R, a GPCR, is known to activate intracellular 
effectors through both the Gq and Gs families of G proteins (Holst et al., 2001; Nakajima 
et al., 1992), followed by induction of the classical mitogen-activated protein kinases 
(MAPK) pathway and I-kappa B (IκB) dependent nuclear factor-kappa B (NF-κB) 
activation. This subsequently results in stimulation of NF-κB-regulated release of 
numerous inflammatory mediators such as pro-inflammatory cytokines and chemokines, 
arachidonic acid derivatives such as prostaglandins via enzymatic conversion by 
cyclooxgenase-2 (COX-2), oxygen free radicals, and histamine, in many cell types such 
as colonic epithelial cells (Koon et al., 2005), macrophages (Marriott et al., 2000; 
Simeonidis et al., 2003), mast cells (Azzolina et al., 2003), T lymphocytes (Guo et al., 
2002), astrocytoma cells (Lieb et al., 1997) and lung epithelial cells (Williams et al., 
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2007). Therefore, in the following section, signaling pathways with particular focus on 
molecules such as MAPKs and NF-κB would be discussed.  
 
1.2.8.1 Mitogen-activated protein kinases 
 
 
MAPKs are one of the most ancient signal transduction pathways which are conserved 
through evolution and are involved in numerous physiological processes. They are a 
family of proline-directed protein serine/threonine kinases activated via numerous 
intracellular phosphorylation and signaling transduction mechanisms from the cell 
surface to the nucleus (Chang and Karin, 2001; Pearson et al., 2001). MAPKs play 
important roles in all aspects of cell development, ranging from embryogenesis, cell 
differentiation, cell proliferation to cell death (Pearson et al., 2001). Likewise in immune 
responses, MAPKs form major components, starting from the early stage of innate 
immunity and subsequent induction of adaptive immunity and cell death when immune 
function is complete (Zhang and Dong, 2005). MAPKs consist of three well characterized 
subfamilies that culminate towards activation of a multi-cascade of MAPKs. They are the 
extracellular signal-regulated protein kinases (ERK1/2); the p38 MAP kinases; and the c-
Jun NH2-terminal kinases or stress-activated protein kinases (JNK/SAPK). Downstream 
pathways in each of the MAPK subfamilies include central three-tiered core signaling 
molecules. A wide variety of upstream signals feed into the core MAPK-kinase-kinase 
(MAP3K), MAPK-kinase (MEK), and MAPK, each one activating the next by 
phosphorylation. Their substrates which are found both in the cytoplasm and nucleus 
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involve phospholipases, other kinases, transcription factors and membrane and 
cytoskeletal proteins (Kyriakis and Avruch, 2001; Roux and Blenis, 2004).        
 
The first mammalian MAPK pathway to be identified was the ERK1/2 pathway. This 
signaling cascade is largely regulated by monomeric GTPase, Ras, which recruits 
MAPKKKs of the Ras family (A-Raf, B-Raf, and Raf-1),
 
to activate two MAPKKs 
(MEK1 and MEK2), which in turn activates the MAPKs (ERK1 and ERK2) (Pearson et 
al., 2001; Roux and Blenis, 2004). Put together, this cascade is in short known as the 
Raf/MEK/ERK cascade. ERK1 and ERK2 are approximately 83% identical in amino acid 
sequence with significant similarities in the core regions for binding substrates (Pearson 
et al., 2001). They are strongly activated by serum, growth factors, cytokines, stress, 
ligands for GPCRs such as SP binding to NK1R and transforming agents (Pearson et al., 
2001). Notably, it has been shown that an activation of just 5% of Ras molecules through 
the signaling cascade is sufficient to lead to the amplification and full activation of 
ERK1/2 (Hallberg et al., 1994). Generally, ERK1/2 are involved in anabolic processes 
such as cell division, differentiation and growth.  
 
The p38 MAPKs are the second member of the MAPK pathway in mammalian cells (Han 
et al., 1994; Lee et al., 1994). The p38 signaling cascade comprise of several MAPKKKs 
(MEKK
 
1 to 4, MLK2 and 3, DLK, ASK1, Tpl2, and Tak1), MAPKKs (MEK3 and 
MEK6), and four p38 isoforms (α, β, γ and δ) (Kyriakis and Avruch, 2001). p38 is about 
50% identical in amino acid sequence to ERK2 and is activated by cellular responses to 
stress and release of inflammatory cytokines (Lee et al., 1994). 
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The JNK/SAPK subfamily consist of JNK1, 2 and 3 which exist in at least 10 different 
forms due to alternative splicing and are widely distributed in the body. They are induced 
by cytokines, stress stimuli such as UV radiation and DNA damaging agents, and when 
there is a lack of growth factors (Kyriakis and Avruch, 2001).   
 
Taken together, it is now known that mammalian MAPK pathways that work in 
conjunction with NF-κB are significantly important for the onset of stress and 
inflammatory responses rather than to mitogen responses. Hence, as more is unraveled 
about MAPK signaling cascades, it is clear that these transduction pathways will be 
essential targets for novel anti-inflammatory therapeutic interventions.    
   
1.2.8.2 Nuclear factor-kappa B 
 
 
The mammalian NF-κB consist of five members that are structurally related and highly 
conserved through evolution: Rel (c-Rel), RelA (p65), RelB, NF-κB1 (p50), and NF-κB2 
(p52) (Ghosh and Karin, 2002). Notably, the p65-p50 heterodimer make up the 
prototypical complex of NF-κB. Stimulation of transcription is regulated by p65/RelA, 
RelB and c-Rel, while p50 and p52 serve to enhance DNA binding (Sizemore et al., 
1999). Numerous animal models of disease and studies on human diseases have 
established the pivotal role of NF-κB in instigating inflammation (Ghosh and Hayden, 
2008). Upon induction of inflammatory stimuli, epithelial cells at the injured site or tissue 
resident   haematopoietic   cells   including   mast   cells   or   dendritic   cells  initiate  the 
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inflammatory response by stimulating pro-inflammatory signaling transduction 
mechanisms leading to activation of NF-κB (Hayden et al., 2006). This activation induces 
an increase in adhesion molecules expression and chemokine release by vascular 
endothelial cells and within the tissue, which subsequently results in the recruitment of 
neutrophils followed by macrophages and other leukocytes at the early phase (Ghosh and 
Hayden, 2008). Additionally, NF-κB is essential for the release of effector molecules 
targeted against microbial invasion and for the prolonged existence of leukocytes at the 
site of injury or infection (Ghosh and Hayden, 2008). Therefore, it is evident that NF-κB 
is a central regulator for the expression of genes involved in all classical components of 
the inflammation process, by instigating transcriptional up-regulation of inflammatory 
mediators in tissue epithelial cells, vascular endothelial and haematopoietic cells and 
stromal cells (Ghosh and Hayden, 2008).  
 
The central paradigm for the activation of NF-κB, particularly the p65-p50 heterodimer, 
relies on a key regulatory event, the phosphorylation of IκB, which functions to sequester 
and inactivate NF-κB in the cytoplasm, mainly by IκB kinases (IKKs) (Baeuerle and 
Baltimore, 1988). This then leads to IκB ubiquitination and proteasomal degradation, 
thereby liberating the cytoplasmic NF-κB dimer and masking the nuclear localizing 
signals on the NF-κB subunits, which translocate to the nucleus to activate expression of 
specific target genes (Baeuerle and Baltimore, 1988).  
 
Studies show that a number of posttranslational events further contribute to the activation 
of NF-κB (Chen et al., 2001; Kiernan et al., 2003). For example, increased 
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phosphorylation of p65/RelA subunit at particular serine residues significantly enhanced 
the transactivation potential of NF-κB (Bird et al., 1997; Bohuslav et al., 2004). While 
phosphorylated p65 subunit is able to recruit coactivators including histone 
acetyltranferases CREB binding protein (CBP) and p300 which augment the 
transcriptional activity of NF-κB (Sheppard et al., 1999; Zhong et al., 2002). Additionally, 
posttranscriptional acetylation of p65 was found to modulate NF-κB activity (Chen and 
Greene, 2003).  
 
1.2.9 Clinical significance of SP: Implications for drug discovery 
 
 
Neuropeptides have been extensively studied for over 30 years. Since evidence emerged 
that peptides are important messengers in the nervous system and the establishment that 
intercellular communication in the CNS is chemically mediated (Carlsson, 2001; 
Greengard, 2001; Kandel, 2001), much interest has been focused on the potential of 
neuropeptides for various indications in clinical trials. Of particular interest was the 
identification of pharmacological intervention against neuropeptide receptors, GPCRs, 
such as neurokinin-1 receptor, which have been the target of drug therapy for decades 
(Humphrey, 2003; Jones and Gibbins, 2008). In fact, more than 50% of all current drugs 
act on receptors (Drews, 2000). Furthermore, the human genome consists of about 550 
GPCR genes and neuropeptides are ligands for about 20% of them (Hokfelt et al., 2003). 
Therefore, finally after seven decades since the discovery of SP and after 3 decades of 
research on neuropeptides, the first „peptide‟ drug, a NK1R antagonist aprepitant, MK 
869, marketed as „Emend‟, has been clinically tested and was approved by the U.S Food 
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and Drug Administration in 2003 for the treatment of emesis after chemotherapy (Patel 
and Lindley, 2003). It also has clinical efficacy for the treatment of severe depression. 
Furthermore, MK 869 has fewer side effects and is as efficacious as selective serotonin 
reuptake inhibitors (Hokfelt et al., 2003). Nevertheless, the rate of discovery and specific 
problems to drug development such as peptide degradation when ingested orally pose 
challenges to these opportunities for therapeutic interventions. Additionally, despite 
encouraging clinical results, many NK1R antagonists became relatively ineffective in 
follow up studies (Rost et al., 2006). Therefore, further research is needed to realize the 
full potential of SP as a therapeutic target.      
 
 
1.3 Burn Injury  
 
 
1.3.1 Etiology of burn injury  
 
 
A burn injury occurs when some or all layers of skin and other tissues are destroyed by 
hot liquid, hot contact, flame, radiation, electricity or chemicals (Kramer et al., 2002). 
The majority of burns are due to flame related injuries, while scald burns resulting from 
contact with hot liquid are the next most common, making up approximately 40% of all 
causes of burns (Hettiaratchy and Dziewulski, 2004a; Pruitt et al., 2002). Electrical or 





1.3.2 Epidemiology of burn injury  
 
 
Burn injury represents one of the most widespread and devastating forms of trauma 
(Church et al., 2006; Pruitt et al., 2002). It is ranked among the top leading causes of 
morbidity and mortality worldwide, with one of the highest burn death rates occurring in 
the United States of all developed nations (Church et al., 2006). Each year, more than 2 
million patients in the United States alone seek care for burn injuries. Out of these 2 
million, 20% require hospitalization, and as many as 7,000 die because of multiple organ 
failure (MOF) (Ogle et al., 1994). In the United Kingdom, approximately 250 000 people 
are burnt annually, half of which are children below 12 years old, with an average of 300 
deaths occurring yearly (Hettiaratchy and Dziewulski, 2004a). These statistics from the 
United Kingdom provide a rough estimate for the incidences of burn injury in most 
developed countries, despite a higher occurrence of burn injuries in the United States 
(Hettiaratchy and Dziewulski, 2004a). In developing countries such as India, out of a 
population of 500 million, over 2 million people are thought to be burnt every year 
(Hettiaratchy and Dziewulski, 2004a). Additionally, the mortality rate in developing 
nations is significantly higher than that in developed nations. For instance, out of 20 
million people in Nepal, 1700 deaths occur due to burn injuries annually which is about 






1.3.3 Demographics of burn injury  
 
 
People with significantly greater risk to burn injury are children and the elderly compared 
to people of other age groups (Cadier and Shakespeare, 1995; Hunt and Purdue, 1992; 
Pruitt et al., 2002). Elderly burn patients over 65 years show a greater number of fatalities 
particularly those with pre-existing medical conditions or disabilities. They make up 
about 10% of people with burn injuries (Hettiaratchy and Dziewulski, 2004a; Pruitt et al., 
2002). Children, particularly those aged 1 to 4 years old, constitute 20% of burn patients, 
notably with about 70% of the burn injuries originating from scalds due to exposure to 
hot fluids, which have the potential to cause large area burns (Hettiaratchy and 
Dziewulski, 2004a; Pruitt et al., 2002). In 2001 to 2002, statistics show that 92 500 
children, aged 14 years and below in the United States, were admitted for emergency 
treatment due to burn injuries with as many as 500 of them pronounced dead (Church et 
al., 2006). Out of all these children, two-thirds experienced sustained thermal injury, and 
those below 4 years old were found to be more like to encounter scald injury (Church et 
al., 2006). Working adults are considered to be at least risk to burn injury, nevertheless 
this age group of 15 to 64 years, comprise of the majority of burn injuries, making up 
60% of all the burn patients (Hettiaratchy and Dziewulski, 2004a).             
 
 




Upon admission to a hospital, a burn patient‟s breathing function and circulation are first 
examined with a thorough assessment for other major injuries apart from the burn injury 
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itself (Church et al., 2006). Particularly, management of the airways is a top priority 
(Marko et al., 2003). After which, factors such as the etiology of burn, burn size, burn 
depth, injury location, age and presence of other injuries or previous medical history are 
determined, which affect the extent of morbidity and mortality (Gueugniaud et al., 2000). 
Burn depth and burn size are the two most important assessment criteria. Areas of partial 
thickness burn, which constitute first and second degree burns; and areas of full thickness 
burn, which constitute third degree burns are described (Monafo and Bessey, 2002). For 
burn size, body diagrams, such as the “rule of nines” are used to calculate the 
approximate percentage of the total body surface area (% TBSA) (Herndon and Spies, 
2001; Roth and Hughes, 2004). The initial determination of burn size enables a forecast 
of the initial fluid resuscitation requirements (Gueugniaud et al., 2000). Additionally, 
burn depth information helps to determine treatment requirements including the amount 
of excision and grafting needed (Church et al., 2006). Burn depth is traditionally assessed 
by trained personnel but more recently by Laser Doppler Imaging (LDI), which has been 
shown to facilitate a more objective assessment (Banwell et al., 1999; Hemington-Gorse, 
2005; Jeng et al., 2003).  
 
 




The body‟s reaction to a severe burn wound injury is much more complex than the launch 
of a local inflammatory response at the burn site. In severe cases of burn injury, even in 
the absence of inhalational injury (Turnage et al., 2002) and infection (Barton, 2008; 
Wolfe et al., 1982), the ongoing local burn wound inflammation is a sufficient triggering 
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source to create systemic inflammatory response syndrome (SIRS) and multiple organ 
dysfunction syndrome (MODS) (Kramer et al., 2002; Rodriguez et al., 1993; Turnage et 
al., 2002). The underlying mechanism is thought to be a network combination of burn-
induced liberation of inflammatory mediators, such as cytokines, chemokines, 
complement factors, leukocytes and neutrophil trafficking (Arturson, 1996). As such, this 
section will highlight the respiratory, cardiovascular, metabolic, inflammatory and 
immunological responses to burn injury. Additionally, important mediators that 
contribute to the pathophysiology of burns will be covered.  
 
1.3.5.1 Respiratory responses to burn injury 
 
In the first 24h, generalized edema in remote tissue is frequently encountered, it is most 
rapid in the first 6 to 8 hours and continues for 18 to 24 hours (Marko et al., 2003; 
Monafo, 1996). Within 48 hours following burn injury, the body usually remains 
infection free but virtually all cell-mediated and humoral immune functions are deranged 
(Kramer et al., 2002; Marko et al., 2003). Notably, impaired gas exchange, decreased 
lung and chest compliance and increased pulmonary vascular resistance are more obvious 
clinical consequences (Turnage et al., 2002). Eventually, these inflammatory events 
develop to acute lung injury (ALI) and its more severe form of acute respiratory distress 
syndrome (ARDS) (Dancey et al., 1999; Ware and Matthay, 2000). Mortality resulting 
from ARDS has remained the primary cause of death in burn-injured patients, with the 
lungs frequently being the first organ to fail (Marshall and Dimick, 1983; Saffle et al., 
1993). Patients with severe local burn injury (more than 30% TBSA) are particularly at 
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significant risk of respiratory failure even when the lungs have not sustained a direct burn 
or inhalational injury (Kramer et al., 2002; Turnage et al., 2002). 
 
Results of clinical and animal studies have established that the persistence of SIRS 
further leads to ARDS (Arturson, 1996; Wolfe et al., 1982). ARDS being an eventual 
consequence of SIRS have brought attention to strategies that hasten the resolution of the 
immediate SIRS following major trauma, particularly those that alleviate early 
inflammatory lung injury (Ware and Matthay, 2000). By doing so, preventing the onset of 
early ALI will prove to have more practical benefit to the patient than efforts to treat 
ARDS once it has ensued (Wolfe et al., 1982). Once respiratory failure occurs, 
therapeutic interventions are limited. Therefore, intense research on elucidating 
mechanisms of burn induced pulmonary pathophysiology and potential preventive 
strategies are of great interest.  
 
1.3.5.2 Cardiovascular responses to burn injury  
 
Cardiac dysfunction is a critical factor affecting morbidity and mortality following burn 
injury (Hoesel et al., 2009; Hoesel et al., 2007; Horton, 2004; Niederbichler et al., 2006). 
Typically, capillary leakage is increased significantly, causing a marked loss of plasma 
proteins and fluids into the interstitial compartments. Concomitantly, peripheral and 
splanchnic vasoconstriction takes places, along with reduced myocardial contractility. 
Together these cardiovascular changes result in impaired peripheral microcirculation, 
systemic hypotension and organ hypoperfusion (Hettiaratchy and Dziewulski, 2004b). 
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Notably, the mechanism leading to hypoperfusion was described in clinical and 
experimental studies, which showed that severe burn injury with TBSA greater than 47%, 
showed marked changes in contraction and relaxation of the left ventricle (Adams et al., 
1984; Adams et al., 1982; Adams et al., 1981). Specifically, significantly lowered 
isovolumic relaxation, marked reduction in diastolic compliance and dysfunction of left 
ventricular contractility was found. This directly affected the filling ability of the left 
ventricle and lowered ejection fraction, thereby causing an overall drop in cardiac output 
following burn injury.  
 
Additionally, burn injury stimulates myocardial release of numerous inflammatory 
mediators, particularly, TNF-α, which exerts negative inotropic effects on the 
myocardium. Treatment strategies targeted against TNF-α prevented myocardial 
contraction and improved outcome (Giroir et al., 1994). Experimental animal models also 
showed that administration of recombinant TNF-α resulted in cardiac contractile 
depression (Eichenholz et al., 1992; Pagani et al., 1992; Tracey et al., 1986); while 
isolated cardiac myocytes and ventricular muscle tissue resulted in negative inotropic 
effects when treated with TNF-α in a concentration dependent manner (Heard et al., 
1992; Horton et al., 2001; Yokoyama et al., 1993). Furthermore, the effect of oxygen free 
radicals on cardiac injury is also well studied due to the persistence of oxygen debt and 
tissue ischemia regardless of consistent resuscitation efforts. Studies demonstrate that 
levels of L-arginine are reduced significantly after burn injury, resulting in nitric oxide 
synthase mediated production of superoxides, which is also destructive to tissues 
(Enkhbaatar and Traber, 2004). Administration of exogenous arginine attenuated lung 
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injury after burn in sheep (Enkhbaatar and Traber, 2004; Murakami et al., 2007). 
Therefore, it is clear that cardiovascular changes contribute extensively to the 
pathophysiology of burn injury.  
 
1.3.5.3 Metabolic responses to burn injury  
 
Severe burn injury causes major increments in metabolic rates, increasing to two times as 
high as that of a normal person (Saffle et al., 1993), thereby constituting a huge challenge 
for effective treatment in burn patients. A large amount of wasting of lean body mass can 
result within weeks of the injury and failure to satisfy this hypermetabolic state of 
increased energy and protein requirements causes severe cellular and immune 
dysfunction, delayed wound healing, lowered resistance to infection and even death 
(Hartmannsgruber et al., 2000; Marko et al., 2003; Saffle et al., 1993). Therefore, 
strategic steps taken to ensure effective treatment include immediate wound closure by 
debridement and grafting, and adequate nutritional support (Marko et al., 2003). Tube 
feeding via the duodenojejunal and non-bolus enteral feeding should be provided as early 
as possible. This is important as not only are nutritional demands met, but the intestinal 
barrier integrity kept intact, which is essential for preventing bacterial translocation 
(Wischmeyer et al., 2001). Together, these measures can lower morbidity and mortality, 
enhance wound healing and minimize hypermetabolism and subsequent catabolism. 
 
The reasons behind hypermetabolism are because of hormonal imbalances after major 
burns (Demling and Seigne, 2000). For example, catabolic hormones such as epinephrine, 
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cortisol and glucagon are elevated which increase gluconeogenesis, glycogenolysis and 
muscle proteolysis (Bessey et al., 1989). Higher levels of catabolic hormones impair the 
effects of insulin and consequently blood sugar levels are elevated, while protein 
synthesis, lipogenesis, and glycogenesis are subdued (Saffle et al., 1993). The clinical 
outcome of these hormonal imbalances is an increased metabolic rate, with skeletal 
muscle being used as the energy source, while the effect of burn injury prevents the body 
from processing fat as the fuel source (Saffle et al., 1993).   
 
1.3.5.4 Inflammatory responses to burn injury  
 
Immediately after burn injury, the inflammatory cascade is initiated (Marko et al., 2003; 
Wolfe et al., 1982). Studies report that the immune status after thermal injury can 
generally be seen as two phases. Firstly, the initial immune response post-burn is pro-
inflammatory which secondly, after prolonged post-burn eventually becomes 
predominantly anti-inflammatory (Church et al., 2006). Such an anti-inflammatory state 
or better described as immunosuppressed state predisposes patients to increased 
susceptibility to subsequent sepsis and multiple organ failure (Baue et al., 1998; Harris 
and Gelfand, 1995; Nguyen et al., 1996; Saffle et al., 1993; Still et al., 1993; Teodorczyk-
Injeyan et al., 1986). These are major complications associated with burn trauma and 
interestingly, recent evidence suggests that the activation of a pro-inflammatory cascade 
after burn appears to be a predisposing factor for launching the development of 
subsequent immune suppression, dysfunction and susceptibility to septic shock and organ 
failure (Meakins, 1990).   
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Pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6 are important in mediating the 
acute phase response to injury. TNF-α is known to be one of the first initiating cytokines 
that stimulate a cascade of secondary cytokines and humoral factors leading to 
subsequent systemic response. Additionally, TNF-α has a potent role in inducing the 
shock-like state associated with thermal injury and sepsis (Marano et al., 1988). However, 
studies have found subsequent low levels of TNF-α post-burn and suggest it may 
contribute to an immunosuppressed state (Yamada et al., 1996). IL-1 is important in 
activating T- and B-cells, but like TNF-α, its levels also remain low after burn and 
therefore is also likely to play a role in the subsequent response to infection (Vindenes et 
al., 1998). Of these pro-inflammatory cytokines, circulating levels of IL-6 is the only 
cytokine consistently elevated systemically post-burn. Results of clinical and 
experimental studies have shown that the marked increase in IL-6 following burn injury 
and sepsis, actually correlates with suppressed cell-mediated immunity and significant 
mortality while Inhibiting IL-6 after burn and sepsis has shown an improved outcome 
(Biffl et al., 1996; Dinarello et al., 1986; Kowal-Vern et al., 1994). TGF-β is a potent 
chemo-attractant of monocytes and neutrophils and aids in tissue repair. Moreover, TGF-
β is also immunosuppressive, as it has been shown to suppress maturation of B- and T-
cells. Studies show that TGF-β plasma levels are elevated 6-8 days post-burn and suggest  
potential causative contributions to immunosuppressed state and increased susceptibility 
to sepsis (Varedi et al., 2001). 
 
Addtionally, important enzymes such as iNOS, inducible nitric oxide synthase, have been 
shown to suppress splenic T-cell proliferation only until 4 days post                        
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thermal injury (Schwacha and Somers, 1998a). Furthermore, it was demonstrated that this 
suppression by RNI was IFN-γ driven 10 days post-burn injury (Masson et al., 1998). 
Moreover, recent studies have implicated iNOS in loss of gut barrier function (Inoue et 
al., 2001) and increased vascular permeability (Chen et al., 1999), indicating its role in 
development of subsequent immune dysfunction and sepsis. 
 
Macrophages are major producers of pro-inflammatory mediators. Studies by Schwacha 
and Sommers have shown that thermal injury dysregulates macrophage activity by 
increasing its productive capacity of pro-inflammatory factors, leading to a “hyperactive” 
phenotype, termed macrophage hyperactivity (Schwacha and Somers, 1998b). This is 
evidenced by increased pro-inflammatory cytokines such as IL-1, TNF-α, IL-6, TGF-β 
(Ogle et al., 1994), RNI (Masson et al., 1998), and Prostaglandin E2 (PGE2) (Miller-
Graziano et al., 1988). Therefore, studies have implicated macrophage hyperactivity to 
the subsequent increased susceptibility to sepsis following thermal injury due to its active 
role in producing IL-1, TNF-α, IL-6, TGF-β and RNI.  
 
1.3.5.5 Immunological responses to burn injury 
 
After burn injury, the number of T lymphocytes drops in the serum of burn patients, 
furthermore, as the severity of burn increases, a concomitant reduction in T cell 
dependent immune functions occurs (Heideman and Bengtsson, 1992; Wolfe et al., 1982). 
γ/δ T-cells which form part of the innate and adaptive immune system are seen as a “first 
line of defense”. Studies demonstrated that 4–9 days post-burn, γ/δ T-cells appear in the 
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spleen, suppressing proliferation of normal splenocytes (Kobayashi et al., 1995; Kupper 
et al., 1985). Findings also demonstrated high mortality in mice deficient in γ/δ T-cells of 
75% 48h post burn (Schwacha et al., 2000). Thereby, impaired T-cell function may be a 
crucial marker in the development of burn-induced immunosuppression.  
 
 
1.3.6 Prognosis and criteria for hospital and burn unit admissions  
 
 
The larger the percentage TBSA of the burn and the deeper the burn depth, the worse the 
prognosis (Hartford, 2002). Generally, partial thickness burns greater than 15 to 25% 
TBSA, or full thickness burns of approximately 2 to 10% TBSA or greater must be 
admitted to the hospital (Marko et al., 2003). Burn injuries that require quick admission 
to a burn unit generally include: partial thickness burns with more than 10% TBSA; all 
third degree full thickness burns regardless of age; electrical burns especially those 
originating from lightning, chemical and inhalational burns; patients with a history of 
medical conditions that can complicate the burn treatment, delay recovery or are fatal; 
and burn injuries occurring on specific parts of the body such as face, hands, feet, 
genitalia, perineum, across joints, and on areas where other injuries have occurred such as 
fractures (McCampbell et al., 2002). Additionally, young children should be put under 
observation for some time regardless of the size of the burn area.  
 
 




A patient with severe burns suffers from hypovolaemic shock, hypoxia, hypothermia and 
extreme pain, all of which should receive immediate attention while treatment of the burn 
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wound itself could be attended to after this (Gueugniaud et al., 2000). Initial care 
generally involves fluid resuscitation, airway management, pain control measures, 
followed by cooling, cleansing, closure and dressing up of the burn wound. 
 
1.3.7.1 Fluid resuscitation  
 
Fluid resuscitation is essential to reduce the severity of hypovolaemic shock. Any delay 
may result in death. The most widely used solution is lactated Ringer‟s solution (Monafo, 
1996). If initial fluid resuscitation had been delayed, then greater volumes are required 
especially for large burn areas, this is because only approximately 20 to 30% of the fluid 
actually remains within the vascular system (Monafo, 1996; Sokawa et al., 1981). 
Concerns have been raised over the use of fluid resuscitation which may result in higher 
lung and tissue edema, following a reduction in tissue perfusion and the likelihood of 
compartment syndrome development (Marko et al., 2003). Reports have shown that 
during the first 48 hours of resuscitation, the incidence of elevated extravascular lung 
water is rare, even in patients who received greater than 400% over the accepted dose of 
Ringer‟s solution. However, it is important to note that close monitoring of hydrostatic 
forces, central venous and lung wedge pressures is essential. Additionally, right 






1.3.7.2 Airway management       
 
The next priority is to ensure adequate airway flow. Administration of oxygen by usage 
of an oxygen face mask is sufficient if the patient‟s breathing is not badly affected. 
Otherwise, the following cases would require endotracheal intubation: facial burns, fire in 
an enclosed area, burns over 30% TBSA, elevated carboxyhemoglobin levels of more 
than 10%, unconsciousness, and evidences of respiratory failure (Gueugniaud et al., 
2000; Herndon and Spies, 2001; Yowler and Fratianne, 2000). Such mechanical 
ventilation lowers the risks of hypoxia and makes up for the higher need of oxygen due to 
increased efforts for breathing especially in cases of smoke inhalation (Demling et al., 
1994). Additionally, lung injury should be determined by laryngoscopy once the patient 
is intubated (Gueugniaud et al., 2000).  
 
1.3.7.3 Pain control measures 
 
Burn wounds which cause significant pain are those with partial thickness wounds devoid 
of the epithelium layer. The pain is increased greatly when wound care and dressing 
changes are performed. Typically, narcotics are used as a first line of treatment while 
intravenous doses of morphine are used in an emergency setting (Hartford, 2002). Non-
steroidal anti-inflammatory drugs (NSAIDS) may be useful while analgesics may be 
supplemented for sedation (Hartford, 2002). Clearance of these drugs is higher 
particularly for patients with a history of alcohol or drug abuse, thereby; large quantities 
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of analgesics may be required (Jaffe, 1990). Anesthetics which are topically applied or 
injected locally are also not suggested.    
 
1.3.7.4 Infection control measures 
 
Application of antimicrobial agents is not just important for reducing the risk of infection, 
but lowering the conversion of partial to full thickness burn wounds and for early 
excision treatment (Heggers et al., 2002; Monafo and West, 1990). Choice of the 
antimicrobial agent should be based on the agent‟s selective inhibition against the 
microorganism found from cultures in the burn wound and any nosocomial infections 
acquired in the burn unit (Church et al., 2006). Topical ointments or creams and dressing 
most widely used are based on the antibacterial effects of the silver ion (Falcone and 
Spadaro, 1986; Heggers et al., 2002). Studies show that the mechanism is due to its 
strong binding to thiol groups in respiratory enzymes of the bacteria and its ability to 
prevent cell division by binding to DNA and structural proteins (Lansdown, 2002; 
Lansdown et al., 2005). Examples of topical agents include: silver nitrate solution, silver 
sulfadiazine and mafenide acetate creams, and nanocrystalline silver dressings (Church et 
al., 2006).          
 
1.3.7.5 Burn wound cooling, cleansing, closure and dressing 
    
It is important to first cool down the burn wound. Studies show that immediate cooling 
by tap water or saline of about 8ºC is effective (Jandera et al., 2000; Saranto et al., 1983), 
while application of ice may be turn out to be more harmful than beneficial (Sawada et al., 
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1997). Apart from heat dissipation, cooling stabilizes mast cells in the skin, lowering 
production of histamine, and reduces wound edema, with additionally alleviation of pain 
(Hartford, 2002; King and Zimmerman, 1965; Ofeigsson, 1965). Cleaning and change of 
dressing of the burn wound should be performed everyday. Washing is done usually with 
room temperature water, with povidone iodine, and a mild soap. Chlorhexidine gluconate 
is highly recommended due to its antiseptic properties against microorganisms in skin 
(Demling, 1985).  
 
Closure of a burn wound by primary healing is the most desirable; however, when this is 
not possible for some shallow to deep burns, then a reconstructive procedure using skin 
grafts or flaps is required (Robson, 2002).  Treatments of shallow burns by using skin 
allograft, xenograft or commercially available synthetic skin membranes are effective 
(Gerding et al., 1990; Poulsen et al., 1991; Robson, 2002). These materials do not require 
the need for dressing changes and lower pain. Surgical treatment of full thickness deep 
burns, with about 25% TBSA involve closing the burn wound with split-thickness skin 
grafts (Monafo, 1996). The excision of the eschar and skin grafting procedure should be 
performed immediately after resuscitation without delay. Furthermore, sufficient amounts 
of autologous skin grafts should be present with adequate amounts of matching blood 














Most survivors of burn injury gradually resume well to their lives of daily work and self-
confidence (Blakeney et al., 2002). The first year is reported to be the most stressful 
however, in some cases the psychological effects can linger on for months to years 
(Blakeney et al., 2002). Disfiguring, scarring, deformity and functional disability are 
some of the serious long term effects of burn injury (Marko et al., 2003). Additionally, 
burn patients tend to undergo depression, which studies show that the severity is 
proportional to the burn area, well being and anxiety of the patient (Ptacek et al., 2002). 
54% of burn patients displayed moderate to severe depression one month following 
discharge from the hospital, while 43% continued to remain depressed after two years 
(Wiechman et al., 2001). Additionally, about 50 to 60% of burn patients have reported a 
required change in employment (Browne et al., 1985). Furthermore, cost of treatment and 
particularly materials required such as skin grafts and blood can be very expensive 
(Barret, 2002).  
 
 








The problem of excessive systemic inflammatory responses, which is a direct 
consequence of SIRS leading to MODS, continues to be a major healthcare challenge 
(Bone, 1992; Brun-Buisson, 2000). ALI manifests clinically as ARDS which is a major 
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component of MODS, arising from a variety of predisposing conditions such as burns, 
sepsis, haemorrhagic shock, acute pancreatitis, pneumonia and trauma (Bhatia and 
Moochhala, 2004; Wheeler and Bernard, 2007). Globally, hundreds of thousands of 
people develop this syndrome annually along with significant morbility, mortality and 
costs incurred (Wheeler and Bernard, 2007). Various studies report that burn injury 
accounts for about 2 to 9% of patients with ARDS (Dancey et al., 1999).  
 
ALI/ARDS was first reported about 40 years ago, in a group of patients who displayed 
significant hypoxemia with diffuse alveolar infiltrates on chest X-ray (Ashbaugh et al., 
1967). These infiltrates were found to be edema in lung tissue resulting from increased 
microvascular permeability. The syndrome was then known as the adult respiratory 
distress syndrome. In 1994, the American-European Consensus Conference Committee 
proposed that since the syndrome was not confined to only adults, the term acute 
respiratory distress syndrome should be used instead (Bernard et al., 1994). Additionally, 
ARDS was defined as “a severe form of ALI and a syndrome of acute pulmonary 
inflammation and resultant increased capillary endothelial permeability (Bernard et al., 
1994).” It was also stated that “ARDS is characterized by a constellation of clinical, 
radiological and physiological abnormalities that cannot be explained by but may coexist 
with left atrial or pulmonary capillary hypertension (Bernard et al., 1994).” This 
definition provides the platform for researchers and doctors to speak on common grounds 




1.4.2 Pathogenesis of ALI/ARDS 
 
The development of ALI/ARDS occurs in three stages: acute or exudative, proliferative 
and fibrotic with each one displaying its own distinguishing clinical, histological and 
radiological indications (Ware and Matthay, 2000). The first phase is an acute or 
exudative phase, which is distinguished by the rapid invasion of inflammatory cells in the 
first 24 to 48 hours (Tasaka et al., 2002). One prominent feature is arterial hypoxemia 
(Ware and Matthay, 2000). Radiographic analysis shows that the syndrome reflects that 
of cardiogenic pulmonary edema (Aberle et al., 1988); while pathological results show 
severe disruption of alveolar epithelium and vascular endothelium, producing an influx of 
inflammatory cells such as neutrophils, macrophages, erythrocytes and protein rich 
edema into the interstitium and the alveolar spaces (Wheeler and Bernard, 2007). These 
changes are mediated by a complex interplay of pro-inflammatory mediators. It is 
possible that following the acute phase, ALI/ARDS may fully resolve in some patients, 
however, in others it can enter the second proliferative phase, taking place between 2 to 7 
days whereby fibroblast infiltrate the inflamed lungs (Tasaka et al., 2002). Permanent 
injury to the type I alveolar cells would prompt the deposition of unnecessary cellular 
proteins, fibrin, and debris, resulting in hyaline membranes, while damage to the 
surfactant producing type II cells leads to alveolar collapse. At this stage, it is again 
possible that the type II cell divide with some epithelial cell regeneration and remodeling 
(Ware and Matthay, 2000). However, in some patients, this may progress to an 
irreversible third phase, the fibrotic phase which persists for over 7 days resulting in 
severe collagen deposition in alveolar, vascular and interstitial beds of the pulmonary 
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parenchyma, with further development of microcysts, exacerbated hypoxemia, 
pulmonary compliance and alveolar dead space (Tasaka et al., 2002; Tomashefski, 1990).  
 
1.4.3 Role of inflammatory mediators in ALI/ARDS    
 
Risk factors for the development of ALI/ARDS can be broadly categorized into those that 
cause direct or indirect injury to the lungs (Ware and Matthay, 2000). Examples of direct 
injury insults include pneumonia, aspiration of gastric contents, toxic inhalational, near 
drowning, pulmonary contusion and fat embolism (Ware and Matthay, 2000). Examples 
of indirect injury to the lungs in the setting of a systemic process are such as severe 
trauma and shock, sepsis, acute pancreatitis, cardiopulmonary bypass, numerous 
transfusions and overdose of drug abuse (Ware and Matthay, 2000). The severity of 
ARDS depends significantly on the extent of SIRS which is directly affected by the 
magnitude of inflammatory mediators from the site of injury spilling over into the general 
circulation. Thereby, the following section will focus on some of the prominent mediators 
known to contribute to ALI/ARDS such as TNF-α, IL-1β, IL-6, ICAM-1, IL-8, SP, 
cyclooxygenases and prostaglandins.  
 
1.4.3.1 TNF-α and IL-1β 
 
Activated macrophages are the main source of TNF-α and IL-1β, both of which are 
significantly elevated in the bronchoalveolar lavage fluid of patients with ARDS, 
suggesting that these cytokines are produced locally (Goodman et al., 1996; Meduri et al., 
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1995; Park et al., 2001; Siler et al., 1989). TNF-α is known to be a major inducer of 
shock (Cohen, 2002; Norman et al., 1995; Putensen and Wrigge, 2000). This was further 
demonstrated in animal models administered with exogenous TNF-α which displayed a 
syndrome indistinguishable from septic shock. IL-1β has been found to also induce a 
shock-like state in experimental animals. Additionally, IL-1β increases neutrophil 
activation and stimulates adhesion molecules expression on leukocytes and the vascular 
endothelium (Cohen, 2002; Dinarello et al., 1989; Norman et al., 1995). Numerous 
attempts have shown that specific antagonist to TNF-α and IL-1β, such as anti-TNF-α 
antibody, soluble type 1 TNF receptor and IL-1 receptor antagonists were successful in 
animal models of lung injury (Denis et al., 1994; Leff et al., 1994), but not in clinical 
trials (Abraham et al., 2001; Opal et al., 1997), although, it has been suggested that they 




The release of IL-6 is triggered by numerous cell types such as monocytes, macrophages, 
endothelial cells and fibroblasts in response to endotoxin, TNF-α and IL-1β (Bhatia et al., 
2000a; Bhatia et al., 2001; Cohen, 2002). In the clinic, concentration levels of IL-6 in the 
blood have been demonstrated to be an outstanding indicator of the severity of ARDS for 
patients with acute pancreatitis and sepsis (Leser et al., 1991; Remick et al., 2002). 
Furthermore, during the acute phage of ARDS, elevated levels of IL-6 have been 
correlated with increased production of acute phase proteins, such as C reactive protein in 





Under normal conditions, ICAM-1 expression levels on the surface of vascular 
endothelial cells are low, however, in inflammatory conditions, such as ALI/ARDS, its 
levels are highly up-regulated (Roebuck and Finnegan, 1999). Administration of 
neutralizing antibodies or gene deletion of ICAM-1 has been found to confer significant 
protection from lung injury in diseases of acute pancreatitis, sepsis, diesel exhaust 
particle induced lung injury and trauma (Bhatia et al., 1998b; Giannoudis et al., 1998; 
Takano et al., 2002). A reduction in ICAM-1 activation has a direct effect on neutrophil 
sequestration to the injured site, thereby, antagonizing important adhesion molecules such 
as ICAM-1 maybe useful for strategies targeted against lung injury primarily mediated by 
neutrophils.   
 
1.4.3.4 IL-8 
          
Chemokines such as IL-8 play a major role in the development of ARDS (Strieter, 2002). 
Particularly, IL-8 belongs to the CXC family of chemokines, secreted mainly by 
macrophages and epithelial cells. The chemoattractant effects of IL-8 influence a wide 
number of leukocytes in lung inflammatory diseases including macrophages, neutrophils, 
mast cells and endothelial cells (Pease and Sabroe, 2002). Furthermore, in inflammatory 
diseases such as sepsis and acute pancreatitis, elevated IL-8 levels detected in the blood 







Numerous studies have shown clear evidences for the regulatory role of SP in multiple 
respiratory diseases (Groneberg et al., 2006; O'Connor et al., 2004). For example, the 
pro-inflammatory role of SP signaling via NK1R has been demonstrated in acute 
pancreatitis and associated lung injury (Bhatia et al., 1998a). Furthermore, mice deficient 
in the PPT-A gene, which encodes for SP, are protected against acute pancreatitis and 
associated lung injury (Bhatia et al., 2003). Similarly, significant protection in the lungs 
of mice lacking the PPT-A gene was found in an experimental model of cecal ligation 
and puncture-induced sepsis associated lung injury (Puneet et al., 2006). Additional 
reports showed increased levels of SP in pulmonary oedema fluid of patients with ARDS 
(Espiritu et al., 1992). The significance of NK1R in instigating lung injury and mortality 
was also demonstrated in rats injected with neurotoxic venom (Matos et al., 1999); while 
SP was shown to lead to the development of ARDS following fire smoke inhalation 
(Wong et al., 2004). Therefore, the blockade of SP or NK1K for the treatment of patients 




1.4.3.6 Prostaglandins and cyclooxygenases 
 
 
Prostaglandins are known to be potent lipid mediators of inflammation (FitzGerald and 
Patrono, 2001). The most abundant in the human body is prostaglandin E2 (PGE2), which 
is produced and regulated in nearly every cell type (Smith, 1989). It is also the most 
prominent prostanoid in exerting inflammation, as it increases vasodilation, vascular 
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permeability and edema (Dubois et al., 1998). Furthermore, studies show that PGE2 
exerts its pathologic effects in numerous systems including the cardiovascular, 
respiratory, gastrointestinal and reproductive systems (Robertson, 1995; Versteeg et al., 
1999). Hence, it is important to note that tight regulation of PGE2 is essential to avoid 
unnecessary cellular and biological processes. Metabolism and degradation of PGE2 takes 
places within the local cell environment. However, specific organs, notably the lungs, are 
particularly designed not just for blood gas exchange but to metabolize bioactive 
molecules such as PGE2 to ensure that it does not escape into the circulation (Schuster, 
1998). Interestingly, studies have reported that the structure and specific location of the 
lungs enables it by means of a PGE2 transporter to eliminate unnecessary PGE2  from the 
circulation and further degrade it into inactive components (Schuster, 1998). ALI/ARDS 
is a common consequence in severely burn-injured trauma patients. As such, it is likely to 
result in these burn-injured patients, significant disruption of lung PGE2 metabolic 
processes (Hahn and Gamelli, 2000). Thereby, rendering leakage of excess PGE2 into the 
blood where it exerts its pro-inflammatory effects resulting in dysfunction of the immune 
system.     
  
PGE2 is synthesized from arachidonic acid via the actions of cyclooxygenase (COX) 
enzymes, COX-1 and COX-2 (Funk, 2001). Both enzymes have about 61% sequence 
homology. However, the main differences that set them apart are the sequences at the 
promoter regions (Tanabe and Tohnai, 2002). The human COX-1 promoter does not 
contain a TATA or CAAT box, thereby making it constitutively expressed in many cells 
(Tanabe and Tohnai, 2002). On the other hand, the promoter region of COX-2 has many 
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inducible gene sequences such as a TATA box, NF-IL6 and CRE motif, sites for AP-2, 
SP1, NF-κB binding, and an E-box (Morita, 2002). The expression of COX-2 is induced 
by numerous cytokines and growth factors, via binding to proteins or transcriptional 
factors that stimulate the gene promoter regions (Morita, 2002). Therefore, this renders 
COX-2 to be the primary enzyme accounting for synthesis of PGE2 in response to 
inflammatory stimuli (Krakauer, 2004). In many diseases, including lung inflammatory 
diseases, the elevated concentrations of PGE2 are known to be well correlated with higher 
levels of COX-2 expression (Funk, 2001). Additionally, the transcriptional gene 
expression of COX-2 and many other proteins has been shown to occur after burn injury, 
thus, making it an important molecule of burn-induced inflammation (Hahn and Gamelli, 
2000). Therefore, in the present study, we were also interested to investigate the effect of 
SP on pulmonary COX-2 and PGE2 expression levels following burn injury. 
 
 




None of the potential therapeutic agents have been successful for treatment of ALI/ARDS 
in randomized controlled clinical trials (Bhatia and Moochhala, 2004). There is no 
specific treatment for ALI/ARDS but generally, the basis of treatment for ALI/ARDS is 
limited to excellent supportive care to ensure adequate provision of oxygen and to 
prevent respiratory complications (Wheeler and Bernard, 2007). Majority of patients with 
ALI/ARDS require positive-pressure ventilation with oxygen while a cuffed tracheal tube 
is supplied where more support is needed. Also, the use of tracheal tube delivered 
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ventilation has been shown to be more beneficial over non-invasive ventilation in such 




1.5 Research Rationale  
 
 
1.5.1 Question of interest: 
What is the role of SP in burn-induced acute lung injury? 
 
The focus of this study is on 3 major areas: SP, burn injury and ALI/ARDS. The 
hallmarks of these areas have been well characterized with respect to their pathologic, 
biochemical and immunologic manifestations (Bhatia and Moochhala, 2004; Parker and 
Townsley, 2004; Ware and Matthay, 2000; Wheeler and Bernard, 2007).  
 
For example, with regard to ALI/ARDS, it is known that the release of pro-inflammatory 
cytokine cascade, chemokines, complement factors, eicosanoids and other inflammatory 
mediators such as reactive oxygen species by cells of the innate immune system 
contributes to heightened lung inflammation (Bhatia and Moochhala, 2004; Deitch, 1992; 
Mulligan et al., 1993). But despite this, the triggering mechanisms, signaling events 
involved in inducing pulmonary inflammation and other mediators that can initiate 
inflammation still remain unclear.  
 
As such, many investigators have focused their work on identifying and elucidating the 
role of potential mediators in ALI. Results from different animal models of lung injury 
 44 
have implicated emerging mediators of lung inflammation. Studies show increased toll-
like receptor-4 reactivity in contributing to intense lung inflammation following burn 
injury and lipopolysaccharide administration (Paterson et al., 2003). Other investigators 
have reported the emerging role of platelets in inflammatory lung disease (Kuebler, 
2006); while it was also reported that a deficiency in platelets played a significant role the 
pathophysiology of burn injury. Our earlier work has also shown that preprotachykinin-A 
(PPT-A) gene products, which encodes SP, are critical inflammatory mediators in acute 
pancreatitis and cecal ligation and puncture-induced sepsis associated lung injury (Puneet 
et al., 2006). However, none have investigated the neurogenic inflammatory effects of 
neuropeptides, such as SP, in mediating remote ALI after local burn injury.  
 
Additionally, with regard to previous studies of neurogenic inflammation after burn 
injury, the effect of SP was only studied in the local cutaneous wound site or hind paw 
(Dunnick et al., 1996; Papp and Valtonen, 2006; Pinter et al., 1999; Saria, 1984; Siney 
and Brain, 1996; Sulpizio et al., 2004). Again, none have addressed the role of SP in 
inducing distant lung injury after burn.  
 
 
Knowledge on characteristics of individual immune mediators is undoubtedly a central 
research theme, but in depth understanding of the effect of these mediators at the 
molecular, cellular and physiological level is important in identifying potential targets for 
future pharmacological manipulation. Therefore, the purpose of the present study is to 
determine the exact role of SP in mediating remote ALI after severe local burns and the 
precise mechanisms by which it works.  
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1.5.2 Approach  
 
Identification of early endogenous triggers that activate inflammatory cells leading to the 
early onset of SIRS and ALI represents an important goal but remains poorly defined. 
This is important because it could direct therapeutic strategies to hasten the resolution of 
immediate inflammation; hence, providing greater benefit to burn patients than efforts to 
treat ALI once it has ensued. For these reasons, we have focused our study on 
investigating the early inflammatory response in lungs following severe burn injury.  
 
We investigated our hypothesis using several approaches. Pharmacological inhibition of 
NK1R and the genetic deletion of SP by removal of the PPT-A gene in mice was 
employed. Additionally, WT mice and mice lacking the PPT-A gene were also 
challenged with exogenous SP or an analogue peptide form to see whether there is a 
reversal of effects observed. Uses of such mice models were excellent for analysis of 


















1.5.3 Objectives  
 
The primary aim of the present study is to investigate the potential role of SP in 
mediating remote ALI after severe local burns. More specifically, the aims of the study 
sought to examine:      
 
1. The role of SP in mediating ALI after severe local burns 
2. The role of SP in regulating the levels of pulmonary cytokines, chemokines, and 
zinc metalloproteinases following burn injury  
3. The effect of SP on inflammatory cells in the circulation after burn injury 
4. The effect of SP on respiratory function after burn injury  


































Substance P (SP) is an 11 amino acid neuropeptide, encoded by the preprotachykinin-A 
(PPT-A) gene, and is released from peripheral nerve endings in all major organs (Mantyh, 
1991). Particularly, in patients with airway diseases, significant amounts of SP have been 
found to be up-regulated in the lung tissues, bronchoalveolar lavage fluid and sputum 
(Joos and Pauwels, 2000; Lamb and Sparrow, 2002; Nieber et al., 1992). SP signals via 
membrane bound neurokinin-1 receptors (NK1R), to elicit its pro-inflammatory effects. 
Studies have shown that it plays a pathogenic role in a variety of immune and 
inflammatory disorders, including polymicrobial sepsis, asthma, endotoxemia, 
inflammatory bowel disease, acute pancreatitis and rheumatoid arthritis (Bhatia et al., 
2003; Grimsholm et al., 2007; Koon et al., 2006; Puneet et al., 2006; Takemura et al., 
2008; Van Rensen et al., 2002).   
 
 
Acute lung injury (ALI) is characterized by increased vasodilation, elevated 
microvascular plasma leakage and increased edema, significant neutrophil infiltration, 
and up-regulation of inflammatory mediators following an insult (Matthay and 
Zimmerman, 2005). The mechanism underlying the severity of ALI is thought to be 
determined by the extent of the resulting systemic inflammatory response. Excessive 
activation of leukocytes caused by the release of a cascade of pro-inflammatory cytokines, 
in particular neutrophils, are stimulated in the general circulation and are recruited to 
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lodge in the pulmonary microvasculature, directly contributing to systemic inflammation 
(Matthay and Zimmerman, 2005). The prominent occurrence of ALI is a major problem 
in burn patients even in the absence of inhalational injury (Turnage et al., 2002). 
However, the early triggers of remote ALI following severe local burn injury are not well 
understood. Additionally, the potential role of neuropeptides, such as SP, in ALI after 
burns has not been investigated. Therefore, the aim of this part of the study was to 
evaluate the possible role of SP in triggering early ALI after burns.  
 
 
2.2 Materials and methods  
 
 
2.2.1 Mouse burn injury model 
  
 
All experiments were approved by Institutional Animal Care and Use Committee of DSO 
National Laboratories and conducted in accordance with their established guidelines. 
Burn injury was performed as previously described (Sio et al., 2010; Stevenson et al., 
2003). Briefly, male BALB/c mice, 6-8 weeks old, were anesthetized with ketamine 
(160mg/kg) + xylazine (4mg/kg) and the dorsal hair clipped. Mice were placed in an 
insulating mold device
 
with an opening calculated to expose 30% total body surface
 
area. 
The exposed skin was immersed in 95ºC water for 8 seconds. This has been shown to 
produce an anesthetic full thickness burn (Stevenson et al., 2003). Sham mice, which 
served as controls, were anesthesized, shaved and exposed to 24ºC room temperature 
water. After sham or burn injury, mice were resuscitated with 1ml of 0.9% sterile normal 
saline solution (i.p.) and were individually housed. 8h or 24h after sham or burn-injury, 
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animals were sacrificed by a lethal dose of pentobartitone (90mg/kg, i.p.). Samples of 
lung and blood were collected. Plasma was prepared from anti-coagulated blood samples 
by centrifugation (13000rpm, 10min, 4°C). Samples were then stored at -80ºC for 
subsequent analysis.     
 
In one group of mice, L703606, oxalate salt {cis-2-(diphenylmethyl)-N-[(2-iodophenyl)-
methyl]-1-azabicyclo[2.2.2]octan-3amineoxalate} (Sigma-Aldrich), or saline was 
administered i.p. to mice at a dose of 12mg/kg 1h before sham or burn-injury. L703606 
binds with high affinity to NK1R and has been shown to be a potent antagonist to it 
(Cascieri et al., 1992; Fong et al., 1992; Francis et al., 1994) . L703606 works as a non-
peptide, competitive antagonist of NK1R by displacing the binding of SP to NK1R 
(Cascieri et al., 1992). Additionally, L703606 has improved stability and greater 
bioavailability compared to peptide antagonist of NK1R developed earlier. In preliminary 
experiments, dose dependent assays on lung neutrophil infiltration were carried out using 
4 to12mg/kg of L703606 administered 1h before burn injury. A dose of 12mg/kg was 
found to significantly inhibit lung neutrophil accumulation (data not shown), and was 
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Laboratories), was dissolved in 0.9% 
sterile normal saline and 0.12µg/kg i.v. was administered 15min before (pre-treatment) 
and 15min after (post-treatment) sham or burn injury to WT mice. PPT-A
–/–
 mice were 
administered 0.12µg/kg i.v. SP analogue peptide immediately after sham or burn injury. 
The function of this analogue is known to specifically and competitively antagonize 
NK1R (Folkers et al., 1984; Maggi et al., 1991). 
 
2.2.2 Measurement of SP levels  
 
Samples of lung and plasma were collected from the animals. Lung samples were 
homogenized in 1ml of ice-cold SP assay buffer
 
for 20s (Bachem; Peninsula 
Laboratories). The homogenates were
 
centrifuged (13,000 x g, 20min, 4°C) and the 
supernatants collected. They were adsorbed on C18 cartridge columns
 
(Bachem) as 
described (Bhatia et al., 1998b; Puneet et al., 2006). The adsorbed peptide was eluted
 
with 1.5ml of 75% v/v acetonitrile. The samples were freeze-dried
 
and reconstituted in 
the SP assay buffer (Bachem; Peninsula
 
Laboratories). SP content in the samples was 
then determined
 
with an ELISA kit (Bachem; Peninsula Laboratories) according
 
to the 
manufacturer‟s instructions and expressed as nanograms per milliliter. Results were then 
corrected for the DNA content
 
of the tissue samples fluorometrically using Hoechst dye 





2.2.3 Measurement of myeloperoxidase (MPO) activity 
 
 
Neutrophil sequestration in lung was quantified by measuring
 
tissue MPO activity. Tissue 
samples were thawed, homogenized
 
in 20mM phosphate buffer (pH 7.4), centrifuged 
(13,000 x g, 10min, 4°C), and the resulting pellet was resuspended in 50mM phosphate 
buffer (pH 6.0) containing 0.5% w/v hexadecyltrimethylammonium
 
bromide (Sigma-
Aldrich). The suspension was subjected to four
 
cycles of freezing and thawing and was 
further disrupted by
 
sonication (40s). The sample was then centrifuged (13,000 x g, 5min, 
4°C) and the supernatant used for the MPO
 
assay. The reaction mixture consisted of the 
supernatant (50µl), 1.6 mM tetramethylbenzidine (Sigma-Aldrich), 80mM
 
sodium 
phosphate buffer (pH 5.4) and 0.3mM hydrogen peroxide
 
(reagent volume: 50µl). This 
mixture was incubated at
 
37°C for 110s, the reaction terminated with 50µl
 
of 0.18M 
H2SO4 and the absorbance measured at 450nm.
 
This absorbance was then corrected for 
the DNA content of the
 
tissue sample and results were expressed as fold increase over 
control
 
(Labarca and Paigen, 1980). 
 




Two hours before sacrifice, each animal received an i.v. bolus injection containing FITC-
albumin (5mg/kg; Sigma-Aldrich) dissolved in normal saline. After mice were 
euthanized by an i.p. injection of pentobarbitone (90mg/kg), the blood was collected by 
cardiac puncture and plasma was separated. The tracheae were exposed and cannulated 
and the lungs were washed twice with 1ml of saline to provide 2ml of bronchoalveolar 
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lavage fluid. The lavage fluid was combined and FITC fluorescence was measured in the 
lavage fluid and plasma (excitation = 494nm; emission = 520nm). The ratio of 
fluorescence emission in lavage fluid to plasma was calculated and used as a measure of 
pulmonary microvascular permeability (Bhatia et al., 1998b; Puneet et al., 2006). 
 
2.2.5 Histopathological examination 
 
A small portion of lung was excised and fixed with 10% neutral buffered formaline 
(Sigma-Aldrich), then subsequently dehydrated through a graded ethanol series, 
embedded in paraffin wax, and sectioned as previously described (Bhatia et al., 2000b; 
Bhatia et al., 1998b). Sections of 5-µm thickness were stained with hematoxylin/eosin 
and examined by light microscopy using a Carl-Zeiss microscope (objective lens 
magnification of x20; eyepiece magnification of x10). 
 
2.2.6 Reverse transcriptase polymerase chain reaction (RT-PCR) analysis 
 
Total RNA from lung was extracted with TRIzol reagent (Invitrogen Life Technologies) 
according to the manufacturer‟s protocol. One microgram of RNA was reverse 
transcribed using the iScript cDNA Synthesis kit (Bio-Rad) at 25°C for 5mins, 42°C for 
30mins, followed by 85°C for 5mins. The cDNA was used as a template for PCR 
amplification by iQ Supermix (Bio-Rad). The primer sequences for detection of PPT-A, 
NK1R and 18S, optimal annealing temperature, optimal cycles, and product sizes are as 
shown in Table 2.1. PCR amplification was conducted in MyCycler (Bio-Rad). The 
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reaction mixture was first subjected to 95°C for 3mins, followed by an optimal cycle of 
amplifications, consisting of 95°C for 30s, optimal annealing temperature (Table 2.1) for 
30s and 72°C for 30s. Final extension was at 72°C for 10min. PCR products were 
analyzed on 1.5% w/v agarose gels containing 0.5 µg/ml ethidium bromide. 
 
2.2.7 Bronchoalveolar lavage fluid (BALF) and neutrophil counting 
 
BALF and neutrophil counting was performed as previously described (Bao et al., 2009). 
Briefly, BALF was collected by performing two intratracheal instillations of 1ml of 
saline, followed by gentle aspiration. Total fluids from the two collections were pooled 
and centrifuged to pellet cells. Cells were re-suspended in PBS centrifuged to cytospin 
slides, fixed, and stained in a modified Wright stain. Differential cell count was 
performed on at least 500 cells in each cytospin slide. 
 
2.2.8 Western immunoblot 
 
 
Lungs were homogenized at 4°C in 0.75 ml radioimmunoprecipitation assay lysis buffer 
supplemented with protease inhibitor cocktail (Roche, Switzerland) and phosphatase 
inhibitor cocktail (Sigma Chemical Co.). The tissue homogenates were centrifuged at 
14,000 g for 10 min at 4°C. Protein concentration in the soluble fraction was determined 
by the method of Bradford. Protein samples (80 μg) were separated by SDS-PAGE on 
Novex
®
 10% Tris-glycine polyacrylamide gels (Invitrogen) and transferred onto 




buffer (Invitrogen) containing 20% (v/v) methanol. Membranes were then washed, 
blocked, and probed overnight at 4°C with rabbit polyclonal anti-NK1R (Sigma; 1: 650 
dilution), followed by secondary detection for 2h with a 1:1000 dilution of HRP-
conjugated, goat anti-rabbit IgG (Santa Cruz Biotechnology). Membranes were washed 
and then incubated in SuperSignal™ West Pico chemiluminescent substrate (Pierce, 
Rockford, IL, USA) before exposure to X-ray films (CL-XPosure™, Pierce). Gels were 
calibrated by protein kaleidoscope standards (Bio-Rad). Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) (Santa Cruz Biotechnology; 1:1000 dilution) was 
applied as an internal control to normalize protein loading. The intensity of bands was 
quantified using LabWorks™ Image Analysis software (UVP). 
 
2.2.9 Immunohistochemical Analysis  
 
Immunostaining for NK1R was performed in paraffin-embedded sections of 5-µm 
thickness. Sections were deparaffinated and rehydrated. Ag sites were retrieved by 
heating the sections on the slides in 10 mM citrate buffer in a microwave oven and 
cooling for 10 min at room temperature and incubation in 3% H2O2 in methanol for 10 
min to inactivate endogenous peroxidase. Sections were again washed in PBS for 10 min 
before blocking with normal goat serum (Vector Laboratories) for 30 min. Primary Ab 
specific for NK1R, rabbit polyclonal to NK1R (anti-NK1R; Sigma) was then added at a 
dilution of 1/50 in 0.3% BSA for 60 min. The sections were then incubated with 
biotinylated goat anti-rabbit Ab (Vector Laboratories) for 30 min. Sections were again 
washed in PBS and incubated with AB reagent, avidin D-HRP (Vector Laboratories), in 
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PBS for 30 min. After washing in PBS, staining was visualized using diaminobenzidine 
(DAB) (DakoCytomation) and counterstained by methyl green. The sections were 
dehydrated, permanently mounted with mounting medium, and observed by light 
microscopy. The DAB substrate chromogen yields a brown/reddish brown reaction end 
product at the site of the target Ag. The staining was
 
examined by light microscopy using 





The data were expressed as mean ± SEM. The significance of difference among groups 
was evaluated by ANOVA with a post-hoc Tukey‟s test for multiple comparisons when 












Table 2.1 PCR primer sequences, optimal conditions, and product sizes 
 
            
            


























Gene Primer Sequence Optimal Conditions Size (bp) 
r18S                                           28 cycles                                        
Annealing: 59ºC 
Sense: 5'-GTAACCCGTTGAACCCCATT-3‟             
Antisense: 5'-CCATCCAATCGGTAGTAGCG-3' 
150
Sense: 5„-CTTGCCTTTTGGAACCGTGTG-3'                  
Antisense: 5'-CACTGTCCTCATTCTCTTGTGGG-3'  
38 cycles                                        
Annealing: 59ºC 
501
Sense: 5'-GCCAATGCAGAACTACGAAA-3'                 
Antisense: 5'-GCTTGGACAGCTCCTTCATC-3'  






2.3 Results  
 
2.3.1 Burn injury significantly elevates endogenous SP levels in lung and plasma 
 
The endogenous concentration of SP was increased significantly in both lung and plasma 
early after burn injury as compared with sham-injured mice at 1h (Fig. 2.1A and B) and 
8h (Fig. 2.1C and D) in wild type (WT) mice. 
 
2.3.2 Burn Injury markedly increased biological activity of SP-NK1R signaling  
 
 
The levels of SP was significantly elevated early after burn injury as compared with sham 
injured mice at 1h and 8h in both lung (Fig. 2.2A) and plasma (Fig. 2.2B). Additionally, 
SP levels exhibited a trend of higher levels at 8h compared to 1h in both lung and plasma. 
Findings from densitometric analysis of PCR products on agarose gel demonstrated that 
PPT-A mRNA expression levels, at both 1h and 8h, correlated well with protein 
expression levels, with 8h showing a higher rise in levels compared to 1h (Fig. 2.3A). 
Additionally, mRNA levels of lung NK1R expression were concomitantly increased (Fig. 
2.3B) as PPT-A mRNA was increased as early as 1h after burn injury. NK1R mRNA 
levels was significantly increased at 1h, however, the levels were lowered back to basal 




Next, we were interested to know the association between SP and NK1R signaling at 
both the protein and transcriptional levels following burn injury. Pre-treatment with 
L703606, a specific NK1R antagonist at a dose of 12mg/kg, significantly suppressed the 
protein levels of SP in both lung (Fig. 2.2A) and plasma (Fig. 2.2B). Similarly, mRNA 
transcriptional levels of PPT-A and NK1R gene expression were significantly lowered 
with administration of L703606 (Fig. 2.3A and B respectively). A higher degree of 
attenuation in PPT-A and NK1R expression levels occurred at 1h in both cases but at 8h 
only PPT-A expression was reduced and there was no difference in NK1R mRNA 
expression by 8h. Collectively, these findings demonstrate that SP biological activity and 
transcriptional activity following burn injury is NK1R signaling dependent, in both lung 
tissue and plasma.            
 
2.3.3 Increased SP-NK1R signaling response correlated with significant ALI 
following severe burn while disruption of SP-NK1R signaling by L703606 
attenuated this effect 
 
 
A prominent clinical pathology of ALI is the invasion of polymorphonuclear leukocytes 
(PMNs), which is also accompanied with augmented microvascular permeability and 
edema (Puneet et al., 2006). Therefore, to confirm whether SP-NK1R signaling is crucial 
in mediating burn injury-induced ALI, we assessed MPO levels as an indicator of 
pulmonary neutrophil infiltration, lung microvascular permeability to test the severity of 
ALI after burn, and performed histopathological examination of lung tissue sections.  
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Our data confirm the presence of severe ALI following severe burn by an increase in lung 
MPO activity (Fig. 2.4A). However, burn-injured mice administered with L703606 
showed markedly reduced MPO activity in lung as compared to the untreated mice at 
both 1h and 8h (Fig. 2.4A). These findings indicate that burn injury induced lung 
neutrophil accumulation partly depends on SP responses. Furthermore, studies have 
shown SP to be a potent chemoattractant as it enhances the migratory, cytotoxic functions 
and adherence of human leukocytes (O'Connor et al., 2004), therefore, this data suggests 
that neurogenic stimuli via SP results in excessive recruitment of neutrophils leading to 
an exaggerated inflammatory response in lung tissue following severe local burn injury.  
 
 
Additional analysis of lung protection by L703606 was performed by assessing leakage 
of i.v. administered FITC-labeled albumin into the alveolar space as a measure of 
pulmonary microvascular permeability. Evidently, lung permeability was enhanced 
significantly following burn injury (Fig. 2.4B); however, pre-treatment with L703606 
significantly abolished the exacerbation of lung permeability at 8h post burn (Fig. 2.4B). 
As such, the protective effect of L703606 is mediated by inhibition of SP induced plasma 





Histopathological examination of lung tissue sections showed significantly higher 
alveolar congestion, a significant increase in perivascular and interstitial inflammatory 
cellular infiltrates, interstitial edema and widening of alveolar septa in untreated mice at 
1h and 8h post burn. Administration of L703606, significantly restored normal lung 
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histoarchitecture at both 1h and 8h following burn injury, as evident in normal and sham-
injured mice (Fig. 2.4, C1 to 4 and D1 to 4).  
 
 
2.3.4 The augmented SP response correlates well with serious lung injury after 
burn; on the other hand, PPT-A gene deletion in mice showed reduced neutrophil 
infiltration and ameliorated pulmonary microvascular permeability 
 
 
Next, we further confirm our findings by using mice lacking the PPT-A gene, and     
PPT-A
-/- 
mice challenged with exogenous SP. We assessed myeloperoxidase (MPO) 
activity; which is an enzyme primarily expressed in neutrophils and is used as a marker 
for quantification of tissue neutrophil sequestration. Burn-injured WT mice exhibited a 
more than 2 fold increase in recruitment of neutrophils compared to sham-injured WT 
mice; and this increment was significantly reduced in PPT-A
-/- 
mice (Fig. 2.5A). 
Furthermore, bronchoalveolar lavage fluid (BALF) revealed polymorphonuclear 
leukocytes (PMNs) accumulation in the alveolar spaces, where a high influx of 
neutrophils was identified (Fig. 2.5B). Neutrophil numbers markedly increased in burn-
injured WT mice BALF, and this number was greatly decreased in the alveolar spaces of 
PPT-A
-/-
 mice, consistent with changes in MPO activity.  
 
Endothelial cells are key players in sequestration of PMNs and regulation of the 
permeability barrier of the pulmonary vasculature (Ware and Matthay, 2000). Given the 
increased recruitment of cells into the airways, we expected changes in vascular 
 61 
permeability. Evidence of lung protection in PPT-A
-/-
 mice was determined by assessing 
leakage of i.v. administered FITC-labeled albumin into the alveolar space as a measure of 
testing the severity of pulmonary microvascular permeability and damage after burn. 
Clearly, endothelial leakage was elevated in burn-injured WT mice as compared to sham-
injured WT mice and this was significantly alleviated in PPT-A
-/-
 mice (Fig. 2.5C). To 
further evaluate lung injury, histopathological examination of lung tissue revealed 
significantly higher alveolar congestion, intense PMNs infiltration, alveolar septal wall 
thickness and interstitial edema in burn-injured WT mice (Fig. 2.5D). However, 
restoration of normal lung histoarchitecture 8h after burn injury was found in PPT-A
-/-
 
mice, as observed in sham-injured WT and PPT-A
-/-
 mice (Fig. 2.5D). Together, these 
findings show that absence of PPT-A gene products are key in resolving acute lung injury 
after burn.    
 
2.3.5 Protective effect of PPT-A gene deletion was reversed in PPT-A
-/-
 mice 
challenged with exogenous SP following burn injury; whereas SP analogue peptide 
form did not aggravate lung damage 
 
The PPT-A gene expresses four distinct mRNA forms through alternative splicing, all of 
which encode synthesis of SP. Only two of the four mRNA forms also encodes 
neurokinin-A (NKA) and its derivatives neuropeptide K and γ, therefore, most research 
continue to focus on studying SP (O'Connor et al., 2004).  
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To answer the question of whether burn-induced acute lung injury is specifically 
attributable to the pro-inflammatory effects of SP, we challenged PPT-A
-/-
 mice with 
exogenous SP. Initially, dose dependent experiments on lung neutrophil accumulation 
were conducted. Sham or burn-injured PPT-A
-/-
 mice received doses of SP starting from 0, 
0.012, 0.12 and 1.2µg/kg, administered i.v. immediately after burn (Fig. 2.6A). Lung 
MPO activity showed a significant increase in burn-injured PPT-A
-/-
 mice challenged 
with 0.12 and 1.2µg/kg of SP at 8h post-burn compared to 0µg/kg (Fig. 2.6A). No 
differences were seen at a dose of 0.012 µg/kg compared to 0µg/kg in burn-injured PPT-
A
-/-
 mice and comparing doses administered across the sham-injured PPT-A
-/-
 mice 
groups only (Fig. 2.6A). These findings show that the protective effects of PPT-A gene 
deletion in the lungs were reversed upon administration of exogenous SP in a mouse burn 
injury model at doses of 0.12 and 1.2µg/kg. Notably, a significant rise in neutrophil 
infiltration in burned-injured PPT-A
-/-
 mice, clearly starts at 0.12µg/kg implicating that 
the SP injection of 0.12µg/kg was sufficient to mobilize neutrophil accumulation in 
lungs; furthermore, this level also corresponds to the total physiological circulatory 
concentration of endogenous SP detected in plasma of normal mice of about 0.15ng/ml 
(Fig. 2.1). Therefore, a dose of 0.12µg/kg SP was chosen to be exogenously administered 
in PPT-A
-/-
 mice for all future experiments.  
 
Although SP, at a dose of 0.12µg/kg, was administered directly into the blood by i.v., we 
wanted to ascertain the actual presence of exogenous SP in the plasma and lungs. Time 
dependent SP levels were performed in sham and burn-injured PPT-A
-/-
 mice (Fig. 2.7A 
and B). The results show that slightly less than half of 0.12µg/kg exogenous SP 
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administered, was actually present in the plasma of  PPT-A
-/-
 mice at 5mins after burn 
injury compared to 0mins, where no SP was administered (Fig. 2.7A).  Within 30mins, 
the SP levels declined rapidly and then remained fairly constant to 8h. Likewise, in the 
lungs, SP levels rapidly infiltrated the lungs within 5mins as compared with 0mins (Fig. 
2.7B). Although, SP levels detected at 5mins after burn in plasma was less then the actual 
dose administered, which is expected, overall, this data supports that our model of 
exogenous SP challenged to PPT-A
-/-
 mice at a dose of 0.12µg/kg, i.v., was sufficient and 
effective enough to exert pro-inflammatory effects as demonstrated in Fig. 2.6A.   
 
Next, we assessed lung neutrophil infiltration and injury in sham or burn-injured PPT-A
-/-
 
mice challenged with SP. Lung MPO activity, neutrophil count in BALF, microvascular 
permeability and histological examination experiments were performed. As expected, the 
introduction of SP to burned-injured PPT-A
-/-
 mice significantly reversed the protective 
effects seen in burned-injured PPT-A
-/-
 mice alone, without SP administration, similar to 
levels seen in burn-injured WT mice (Fig. 2.5A to D). No differences were seen across all 
three sham groups (Fig. 2.5A to D).    
 
To further ascertain that the effects of burn-induced acute lung injury found is 







)-Substance P. Amino acids positioned at 1, 7, 


















-NH2 (Folkers et al., 1986). D-Tryptophan substitution at position 7 
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and 9 is favorable for antagonistic activity, while leucine in position 11 increases potency 
(Folkers et al., 1984; Folkers et al., 1983). The function of this analogue has been tested 
to occupy NK1R and antagonize it (Maggi et al., 1991). As expected, the same 
intravenous dose of 0.12µg/kg administered to WT mice 15 min before (pre-treatment) 
and 15 min after (post-treatment) sham or burn injury and to PPT-A
-/-
 mice immediately 
after sham or burn injury failed to aggravate lung MPO activity (Fig. 2.8A and B) and 
alveolar congestion as revealed by histological examination (Fig. 2.8C to E).  
 
2.3.6 Lung NK1R expression after burn injury 
 
SP elicits its pro-inflammatory effects by activating NK1R. Hence, knowing NK1R 
expression levels in lungs after burn injury is of significant importance. Western blot and 
Immunohistochemical analysis (appearing as brown color) showed significantly 
increased NK1R levels at 8h in burn-injured WT mice compared to sham-injured WT 
mice and burn-injured PPT-A
-/-
 mice (Fig. 2.9). No differences in lung NK1R levels were 
observed between burn-injured PPT-A
-/-
 mice and in burn-injured PPT-A
-/- 
mice injected 
with SP as well as compared to their respective sham groups (Fig. 2.9).  
 
2.4 Discussion  
 
 
The results of this study provide a major implication: given the large number of 
molecules thought to influence the pathophysiology of burn injury, we show that a single 
endogenous factor, SP, acts early with distinct roles, in instigating diverse pulmonary 
inflammatory events following severe local burn injury. Evidence derived from three 
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different and complementary approaches: pharmacological inhibition of SP-NK1R 
signaling, genetic deletion of PPT-A gene in mice and exogenous administration of SP to 
PPT-A
-/- 
mice, supports these conclusions. 
 
Results of the present study revealed that burn injury augments significant SP release in 
plasma and lungs. Furthermore, concomitant elevation of PPT-A gene levels were 
observed. Also, significantly higher levels of MPO activity, microvascular permeability 
and histological examination revealing higher alveolar congestion, interstitial 
inflammatory cellular infiltrates and edema was observed at 8h compared to 1h which 
correlated with elevated levels of SP and PPT-A mRNA at 8h than at 1h in lungs. 
 
Activation of SP downstream pro-inflammatory effects requires its binding to NK1R. 
Interestingly, our results show that mRNA levels of NK1R were elevated at only 1h and 
later decreased to levels similar to sham-injured mice at 8h although SP, PPT-A and lung 
injury levels were significantly higher at 8h than at 1h. Therefore, these lead us to 
question whether NK1R expression levels have a role in regulating SP and its resultant 
effects of ALI. We verified this by using a specific antagonist to NK1R, L703606, which 
markedly suppressed lung SP expression at the transcriptional and protein level at both 
1h and 8h after burn injury. Therefore, the data suggest that the modulation of SP by 
NK1R acts possibly by a mechanism where only blockade of NK1R down-regulates SP 
and PPT-A gene expression levels. Furthermore, this modulation of NK1R on SP occurs 
regardless of the number of NK1R expressed, because SP synthesis, PPT-A levels and 
ALI persistently increased despite a return of NK1R mRNA levels to basal levels at 8h in 
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burn-injured mice. Therefore, collectively, these results demonstrate that burn-induced 
ALI occurs via biological activity of SP-NK1R signaling, which consistently continues to 
rise, regardless of number of NK1R expressed as long as the NK1R complex is intact. 
However, once blockade of the NK1R complex occurs, the signaling is disrupted, and 
levels of SP along with the severity of ALI are diminished.   
 
Next, we further supported our results by verifying the role of SP in burn-induced ALI by 
using mice deficient in the PPT-A gene and challenging the PPT-A
-/- 
mice with 
exogenous SP. Consistent with our earlier findings, our results show that excessive 
neutrophil accumulation in the lungs and alveolar spaces of burn-injured WT mice, as 
evidenced by increased MPO activity and neutrophil count in BALF. The significantly 
higher migration of neutrophils, from blood to the alveolar airspace is one of the 
hallmarks of  the development of ALI (Ware and Matthay, 2000). Thereby, as expected, 
ALI was observed by a concurrent significant increase in microvascular permeability and 
disruption of lung histoarchitecture. These effects were abolished in burn-injured PPT-A
-
/-
 mice and restored when PPT-A
-/-
 mice were challenged with exogenous SP. These 
results imply that although SP and neurokinin-A are synthesized by the PPT-A gene 
(Nawa et al., 1984), the contribution of SP is critical in instigating pulmonary injury after 
burn. Furthermore, sham-injured PPT-A
-/-
 mice did not show increased lung MPO 
activity even though these mice were administered the same dose of SP, implicating that 
SP alone at a concentration used in this study and in the absence of burn injury, does not 
induce lung injury. Additionally, administration of SP analogue peptide in burn-injured 
WT and PPT-A
-/- 
mice failed to aggravate ALI, further verifying the pro-inflammatory 
 67 
role of SP in burn-induced ALI. Taken together, our findings reveal that burn injury 
primes the body for the pro-inflammatory effects of SP. Thereby, confirming that SP is a 
critical factor for the development of lung inflammation and injury after burn.  
 
Interestingly, our findings here indicate that the low dose of exogenous SP injected into 
PPT-A
-/-
 mice is enough to instigate increased ALI, compared to higher endogenous SP 
levels needed in WT mice to cause similar severity of ALI status. We suggest that this 
may be due to PPT-A
-/-
 mice being more responsive than WT mice to SP. SP instigates 
ALI by activating NK1R (O'Connor et al., 2004). This greater responsiveness in PPT-A
-/-
 
mice maybe because of more responsive NK1R in PPT-A
-/-
 mice, and less responsive 
NK1R in WT mice. This effect could be explained by the absence of continuous 
endogenous SP release in PPT-A
-/-
 mice. Several studies have shown evidences that 
extended exposure of SP invariably leads to NK1R desensitization which results in down-
regulation of the response of a cell to SP (Bowden et al., 1994; Grady et al., 1995; 
Mantyh, 1991; Solway et al., 1993). Therefore, the production of continuous endogenous 
SP in WT mice may result in NK1R to be less responsive; hence, greater SP 
concentrations would be necessary to cause significant ALI. In addition, our data 
demonstrates that a minimum threshold of 0.12μg/kg SP administered to PPT-A-/- mice, 
which corresponds to about 0.075ng/ml of actual SP concentration levels present in 
plasma, is required to instigate severe ALI following burn injury. Also, when a lower 
dose of 0.012μg/kg SP was injected to PPT-A-/- mice, this dose failed to cause lung 
neutrophil accumulation after burn. In WT mice, a concentration level of about 0.3ng/ml 
SP found in plasma was enough to exhibit markedly increased ALI at 8h post-burn.   
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The ability of SP to affect various early events in the inflammatory cascade suggests its 
up-stream activity in the burn-injured host. By binding to NK1R, present throughout cells 
in the body, SP elicits a cascade of downstream pro-inflammatory events. As such, 
knowing how burn injury may affect the NK1R expression levels in lungs is of 
significant importance. Western blot results showed that lung NK1R levels in burn-
injured WT mice were up-regulated at 8h compared to sham-injured WT mice. However, 
levels of NK1R in burn-injured PPT-A
-/-
 mice did not show any changes in NK1R levels 
compared to sham-injured PPT-A
-/-
 mice but exhibited significantly lower NK1R levels 
than burn-injured WT mice. This observation suggests that increased SP levels in 
conjunction with burn injury regulate NK1R expression. Conversely, a low dose of SP 
injection in burn-injured PPT-A
-/- 
mice did not result in any change in NK1R levels. 
Nevertheless, despite having no up-regulation in NK1R levels, burn-injured PPT-A
-/- 
mice injected with SP still exhibited similar lung injury status as in burn-injured WT 
mice at 8h. Therefore, it appears that basal levels of NK1R are sufficient for downstream 
SP-mediated signaling after burn and up-regulation of NK1R does not influence the 
extent of lung injury. 
 
In summary, we show evidence that the pharmacological inhibition of SP-NK1R 
signaling and absence of a single endogenous factor, SP, significantly provides early 
protection against burn-induced ALI in mice. Thereby, blockade of SP maybe beneficial 























Figure 2.1 Significant increases in endogenous SP levels early after burn injury. SP 
levels in plasma (A and B) and lung (C and D) of WT mice 1h and 8h after sham or burn 
injury were measured by ELISA. Sham-burn mice served as controls. Results shown are 


















































































































































Figure 2.2 Blockade of NK1R significantly reduces SP levels after burn injury. 
Levels of SP, measured by ELISA, in lung (A) and plasma (B) were evaluated at 1h and 
8h post burn. Mice were randomly given L703606 (12mg/kg, i.p.) or vehicle (saline) 1h 
before burn injury. Sham burn mice served as controls. Results shown are the mean 
values ± SEM. (n = 8 mice/group at each time point) **, p<0.01 vs sham; #, p< 0.05 vs 




































Figure 2.3 Expression levels of PPT-A and NK1R mRNA levels in lung after burn 
injury. The level of PPT-A (A) and NK1R (B) mRNA in lung was determined 1h and 8h 
post burn by semi-quantitative RT-PCR (determined as ratio of band densities of PPT-A 
or NK1R to 18S). Mouse 18S served as a control. Mice were randomly given L703606 
(12mg/kg, i.p.) or vehicle (saline) 1h before burn injury. Sham burn mice served as 
controls. Results shown are the mean values ± SEM (n = 6 mice/group at each time point). 
*, p<0.05 vs sham; **, p<0.01 vs sham; #, p< 0.05 vs burn + saline; ##, p<0.01 vs burn + 


































































































Figure 2.4 Treatment with L703606 significantly attenuated ALI in mice following 
burn injury. ALI was assessed by determining changes in MPO activity 1h and 8h post 
burn (A), the leakage of i.v. administered FITC-labeled albumin into the alveolar space 
8h post burn as a measure of lung permeability (B), and H&E-stained representative lung 
sections of sham versus burn-injured mice at 1h and 8h post-burn (C and D). Mice were 
randomly given L703606 (12mg/kg, i.p.) or vehicle (saline) 1h before burn injury. Sham-
burn mice served as controls. Lung sections shown include: normal mice (C1), sham 
mice (C2), burn + saline (C3), burn + L703606 (12mg/kg) (C4) 1h post burn; and normal 
mice (D1), sham mice (D2), burn + saline (D3), burn + L703606 (12mg/kg) (D4) 8h post 
burn. Results shown are the mean values ± SEM (n = 6-8 mice/group at each time point). 
*, p<0.05 vs sham; **, p<0.01 vs sham; #, p< 0.05 vs burn + saline; ##, p<0.01 vs burn + 






























































































































































































































































































































































































































































































Figure 2.5 Reduced neutrophil infiltration and alleviated ALI in burn-injured PPT-
A
-/-
 mice. Lung MPO activity (A), neutrophil counts in BALF (B) and lung microvascular 




 mice injected with SP 
(0.12µg/kg, i.v.) or vehicle (saline) immediately after sham or burn injury. Results shown 
are the mean values ± SEM (n = 4-7 mice per group). *, p<0.05; **, p<0.01. (D) 





 mice injected with SP (0.12µg/kg, i.v.) or vehicle (saline) 
immediately after sham or burn injury. Sham burn mice served as controls. Lung sections 
include: sham-injured WT mice (D1), sham-injured PPT-A
-/-
 mice (D2), sham-injured 
PPT-A
-/-
 mice injected with SP (D3), burn-injured WT mice (D4), burn-injured PPT-A
-/-
 
mice (D5) and burn-injured PPT-A
-/-
























































Figure 2.6 Administration of exogenous SP markedly increased lung neutrophil 
infiltration in a dose dependent manner following burn injury in PPT-A
-/-
 mice. (A) 
Lung MPO activity at 8h in PPT-A
-/-
 mice injected with various doses of SP immediately 
after sham or burn injury. Results shown are the mean values ± SEM (n = 6-8 mice for 
each dose group). **, p<0.05 compared to burn-injured PPT-A
-/-
 mice + SP (0µg/kg) and 
sham-injured PPT-A
-/-
 mice + SP (0.12µg/kg); *, p<0.05 compared to burn-injured PPT-
A
-/-
 mice + SP (0µg/kg) and sham-injured PPT-A
-/-
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Figure 2.7 Confirmation of the actual levels of exogenous SP present in plasma and 
lung of PPT-A
-/-
 mice. Actual levels of exogenous SP at various time points in plasma 
(A) and lungs (B) of PPT-A
-/-
 mice administered immediately after sham or burn injury, 
were determined by ELISA. Results shown are the mean values ± SEM (n = 7-14 mice 
per group per time point). **, p<0.01 compared to SP levels at 0min (representing mice 
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Figure 2.8 SP analogue peptide failed to induce ALI in WT and PPT-A
-/-
 mice 
following burn injury. Lung MPO activity at 8h in WT mice injected with SP analogue 
peptide (0.12µg/kg, i.v.) or vehicle (saline) 15min before (pre-treatment) and after (post-
treatment) sham or burn injury (A) and PPT-A
-/-
 mice injected with SP (0.12µg/kg, i.v.) 
or SP analogue peptide (0.12µg/kg, i.v.) immediately after sham or burn injury (B). 
Results shown are the mean values ± SEM (n = 5-7 mice per group). *, p<0.05. (C-E) 
Histopathological evaluation (H&E staining) of lung PMN infiltration and injury at 8h in 
WT mice administered with SP analogue peptide (0.12µg/kg, i.v.) or vehicle (saline) 
15min before (pre-treatment) (C) and 15min after (post-treatment) (D) sham or burn 
injury and PPT-A
-/-
 mice administered with SP analogue peptide (0.12µg/kg, i.v.) or SP 
(0.12µg/kg, i.v.) immediately after sham or burn injury (E). Sham burn mice served as 
controls. Lung sections include: sham-injured WT mice (pre- or post-treatment) (C1, D1), 
sham-injured WT mice injected with SP analogue peptide (pre- or post-treatment) (C2, 
D2), burn-injured WT mice (pre- or post-treatment) (C3, D3), burn-injured WT mice 
injected with SP analogue peptide (pre- or post-treatment) (C4, D4); sham-injured PPT-
A
-/-
 mice injected with SP (E1),  sham-injured PPT-A
-/-
 mice injected with SP analogue 
peptide (E2), burn-injured PPT-A
-/-
 mice injected with SP (E3) and burn-injured PPT-A
-/-
 





















































Figure 2.9 Expression levels of Lung NK1R following burn injury. (A) Western blot 




 mice injected with SP 
(0.12µg/kg, i.v.) or vehicle (saline) immediately after sham or burn injury and 
corresponding densitometry quantification of bands. NK1R and its corresponding HPRT 
bands shown in each lane are representative results obtained from different blots. Results 
shown are the mean values ± SEM (n = 4 mice per group). *, p<0.05. (B) 
Immunohistochemical localization of NK1R at 8h in lungs of sham-injured WT mice 
(B1), burn-injured WT mice (B2) and burn-injured PPT-A
-/-
 mice (B3). Sham burn mice 











































































































Chapter III   Effect of SP on pulmonary cytokines, chemokines and zinc 
metalloproteinases production after burn injury 
 




The classical bioactive neuropeptide, substance P (SP), encoded by the preprotachykinin-
A gene, is a major mediator of pro-inflammatory responses in many pathological 
conditions. It binds preferentially to the neurokinin-1 receptor (NK1R), present in all 
major organs, including the lungs and on numerous immune cells, to elicit numerous 
systemic inflammatory effects such as increased microvascular permeability and plasma 
extravasation, immune cell influx, increased edema, vasodilation and glandular secretions 
thereby, contributing to heightened systemic inflammation.     
 
The clinical consequences of the systemic inflammatory response syndrome (SIRS) are 
characterized by tachycardia, tachypnea, fever, leukocytosis, hypotension, and in very 
severe cases, shock and multiple organ dysfunction syndrome (MODS) (Sherwood and 
Traber, 2002). In severely burn-injured patients, SIRS is initiated immediately after the 
onset of the burn injury (Marko et al., 2003; Monafo, 1996). The presence of SIRS in 
burn patients is an important predictor of poor prognosis (Muckart and Bhagwanjee, 
1997). This is supported further by burn patients reported to have severe SIRS and later 
died of sterile MODS, particularly ALI/ARDS leading to lung failure, who were 
clinically uninfected at the time of death (Sheridan et al., 1998). The results of multiple 
clinical and animal studies have established that the persistence of SIRS can lead to early 
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MODS with an attendant high mortality, occurring in 20 to 30% individuals (Biffl et al., 
1996). Additionally, the severity of SIRS and its persistence in burn patients has been 
shown to be proportional to the magnitude of the burn injury, and is associated with 
increased morbidity and mortality (Sherwood and Traber, 2002). Therefore, the severity 
of the initial inflammatory events is an important predisposing factor in determining the 
initial and prolonged effects of SIRS on the host (Sherwood and Traber, 2002).  
 
Upon severe burn injury, an acute release of a cascade of pro-inflammatory cytokines is 
induced leading to the activation of SIRS. Well known examples of the underlying 
molecules responsible are the classical TNF-α, IL-1β and IL-6. In addition, chemokines 
play a pivotal role to the pathophysiology of burn injury. Therefore, it is in our interest to 
investigate the role of pro-inflammatory mediator, SP, in instigating cytokine and 
chemokine production. Additionally, we were interested in determining the effect of burn 
injury on regulatory molecules of SP, such as neutral endopeptidase (NEP) and 
regulatory molecules of extra-cellular matrix proteins, matrix metalloproteinases (MMP). 
Therefore, in this chapter we focus on understanding the effect of SP and these 
inflammatory mediators in instigating remote ALI after severe local burn injury.  
 
 








For details, see section 2.2.1, page 48.  
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For details, see section 2.2.6, page 52. The primer sequences for detection of IL-1β, IL-6, 
TNF-α, MIP-1α, MIP-2 and 18S, optimal annealing temperature, optimal cycles, and 
product sizes are as shown in Table 3.1. 
 
 
3.2.3 Cytokine, chemokine and matrix metalloproteinases analysis 
 
 
Single-analyte ELISA assays were performed for the measurement of cytokines (IL-1β, 
IL-6 and TNF-α), chemokines (MIP-1α and MIP-2) and matrix metalloproteinases 
(MMP-9 and MMP-2) in homogenized lung tissue, ELISA kits, all from
 
R&D Systems 
were used according to the manufacturer‟s instructions. The lower limits of detection of 
the levels of
 
IL-1β, IL-6, TNF-α, MIP-1α, MIP-2, were 15.625, 15.625, 31.25, 3.91 and 
15.625 pg/ml respectively; while MMP-9 and MMP-2 were 15.6 and 16.5 ng/ml 
respectively.  The ELISA results were
 
reproducible with interassay variability of <9.5% 
and intra-assay
 
variability of <6.5%. Results were then corrected for the
 
DNA content of 
the tissue samples (Labarca and Paigen, 1980) and were expressed as
 
picograms per 
microgram of DNA. 
 




NEP enzymatic activity was measured spectrophotomerically as previously described 
with minor modifications (Yamaoka and Kawana, 2007). Lung tissue was homogenized 
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in T-PER tissue protein extraction reagent (Pierce) and centrifuged at 12,000g for 15 min 
at 4ºC. Each sample (30µg protein) was incubated with 1mM succinyl-Ala-Ala-Phe-p-
nitroanilide
 
(Suc-Ala-Ala-Phe-pNA; Bachem; Peninsula Laboratories)
 
as a substrate in 
0.1 M Tris·HCl (pH 7.6) in the presence
 
of 1 µl (0.02 units/µl) porcine kidney 
aminopeptidase AP-N (Roche Diagnostics). In this coupled activity assay, NEP cleaves 
Suc-Ala-Ala-Phe-pNA
 
between Ala and Phe, yielding Phe-pNA. AP-N subsequently 
cleaves
 
Phe-pNA, generating pNA as the final product. The increase in
 
specific 
absorbance at 405 nm (as a result of the accumulation
 
of free p-nitroaniline) was 
determined each min after incubation at 37°C
 
for 30 min with a micro-plate reader. 
Substrate
 
alone and substrate with AP-N and Tris buffer blanks were run
 
in parallel. 
Protein concentration was determined by the Bradford method. 
 
 




For details, see section 2.2.9, page 54. Immuno-staining was performed using rat 
monoclonal anti-NEP (1/50 dilution; Santa Cruz Biotechnology).  
 
 













Table 3.1 PCR primer sequences, optimal conditions, and product sizes 
 
            
            
































Sense: 5'-AAGGAGAACCAAGCAACGAC-3„                   
Antisense: 5'-GAGATTGAGCTGTCTGCTCA-3'   
IL-1β 34 cycles                                        
Annealing: 63ºC 
Sense: 5'-TGCTGGTGACAACCACGGCC-3'                    
Antisense: 5'-GTACTCCAGAAGACCAGAGG-3'  
IL-6 34 cycles                                        
Annealing: 63ºC 
Sense: 5'-CCTGTAGCCCACGTCGTAGC-3'             
Antisense: 5'-TTGACCTCAGCGCTGAGTTG-3'  
TNF-α 34 cycles                                        
Annealing: 65ºC 
Sense: 5'-GCTGTCAATGCCTGAAGACC-3„             
 Antisense: 5'-TAGTTCCCAACTCACCCTCTC-3'   
MIP-2 36 cycles                                        
Annealing: 65ºC 
MIP-1α Sense 5'-ACTGCCCTTGCTGTTCTTCTCT-3„                          
 Antisense 5„-AGGCATTCAGTTCCAGGTCAGTGA-3'   
34 cycles                                        
Annealing: 61ºC 
Gene Primer Sequence Optimal Conditions Size (bp) 
r18S                                           28 cycles                                        
Annealing: 59ºC 














3.3.1 SP-NK1R signaling significantly augmented pro-inflammatory cytokines and 
chemokines at the transcriptional and protein levels following severe burn injury.  
 
 
Severe injury results in the onset of the production of a cascade of pro-inflammatory 
cytokines, termed as a “cytokine storm”, which leads to the downstream phenotypic 
changes in the host inflammatory response (Bhatia and Moochhala, 2004; Ware and 
Matthay, 2000). Therefore, to investigate the link between SP-NK1R signaling in 
generating a cytokine mediated lung injury after burn, we determined the role of SP-
NK1R signaling in affecting these mediators at the transcriptional and protein level.  
 
 
Our results showed markedly increased mRNA expression levels of IL-1β, TNF-α and 
IL-6; and these were inhibited upon treatment with L703606 (Fig. 3.1A to C). At the 
protein expression level, a similar effect was found which correlated well with the mRNA 
levels showing significantly increased IL-1β, TNF-α and IL-6 at both 1h and 8h, all of 
which were markedly suppressed by pre-treatment of L703606 except for IL-6 which 
exhibited a decrease in levels only at 8h post burn but not at 1h (Fig. 3.2A to C). Notably, 
a marked reduction in IL-6 mRNA levels was found at 1h although there was no change 




Subsequently, we addressed the role of SP-NK1R signaling on chemoattractants 
production in mediating recruitment of inflammatory cells after burn injury. Earlier, we 
assessed lung neutrophil infiltration as an early marker
 
of ALI by determining MPO 
activity; therefore it was appropriate to study the expression of macrophage-inflammatory 
protein 2 (MIP-2),
 
a potent neutrophil chemoattractant secreted mainly by alveolar
 
macrophages (Puneet et al., 2005); and MIP-1α  which is a product of activated 
monocytes and macrophages and also an important activator of T cells, monocytes, and 




Significantly increased transcriptional levels of MIP-2 were found after burn injury at 1h 
and 8h (Fig. 3.1D). This correlated well with the protein levels at 1h and 8h (Fig. 3.2D), 
which also rose in parallel with elevated levels of MPO activity (Fig. 2.4A). Likewise, 
disruption of SP-NK1R signaling by L703606 suppressed MIP-2 protein levels (Fig. 
3.2D) and as such a reduction in MPO activity was observed at both 1h and 8h as well 
(Fig. 2.4A). Gene expression levels of MIP-1α were increased at only 1h but were no 
longer elevated at 8h (Fig. 3.1E). L703606 significantly prevented MIP-1α gene 
expression at 1h (Fig. 3.1E). At the protein level, MIP-1α expression at both 1h and 8h 








3.3.2 Absence of PPT-A gene impaired pro-inflammatory cytokine and chemokine 
production after burn but not in mice challenged with exogenous SP  
 
Next, we further confirm our results by using mice lacking the PPT-A gene, and PPT-A-/- 
mice challenged with exogenous SP. Burn-injured PPT-A-/- mice exhibited alleviated  
lung inflammation evident by a significant reduction in pulmonary levels of pro-
inflammatory cytokines IL-1β, TNF-α, IL-6 and chemokines MIP and MIP-1α compared 
to burn-injured WT mice (Fig. 3.3A to E). Administration of exogenous SP to PPT-A-/- 
mice reversed this effect in all five cytokines and chemokines aggravating lung 
inflammation (Fig. 3.3A to E). Therefore, these data show that PPT-A gene deletion is 
important in preventing the release of SP-mediated cytokines and chemoattractant 
induction of inflammatory cells, which lead to the onset of ALI after burn.   
 
3.3.3 Effect of PPT-A gene products on zinc metalloproteinases expression and 
activity in lungs after burn injury 
 
Members of the zinc metalloproteinase superfamily are a major group of enzymes that 
regulate protein levels by using zinc for their proteolytic activities (Hooper, 1994). 
Neutral endopeptidase (NEP), matrix metalloproteinase (MMP)-9 and MMP-2 are such 
examples. NEP represents one of the most studied neuropeptide-degrading enzymes. It is 
a membrane bound enzyme which is in lungs located mainly at the surface of epithelial 
cells and is known to degrade and inactivate SP, thereby, modulating the number of intact 
SP molecules (Di Maria et al., 1998). NEP is present in high quantities in the healthy 
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lung, and is decreased in a number of airways diseases such as asthma and bronchitis  (Di 
Maria et al., 1998; Nadel, 1990). Our results show that after burn injury in WT mice, 
NEP activity was significantly diminished compared to sham-injured WT mice (Fig. 
3.4A). Its activity was markedly increased in burn-injured PPT-A
-/-
 mice; while 
exogenous administration of SP to burn-injured PPT-A
-/-
 mice again lowered NEP 
activity (Fig. 3.4A). Additionally, immuno-staining of lung sections for NEP (appearing 
as brown color) showed similar results (Fig. 3.4B), suggesting that burn-induced increase 
in SP levels may modulate NEP activity.  
 
MMP-9 and MMP-2 are extra-cellular enzymes that regulate extracellular matrix (ECM) 
proteins, and are particularly important in the pathogenesis of many inflammatory 
diseases in many organs including the lungs (Atkinson and Senior, 2003). They are 
present in low quantities in the healthy lung, but much more abundant in several lung 
diseases (Atkinson and Senior, 2003). Our results reveal that lung MMP-9 levels are 
elevated after burn in WT mice and significantly reduced in burn-injured PPT-A
-/-
 mice; 
this effect was reversed in burn-injured PPT-A
-/-
 mice injected with exogenous SP (Fig. 
3.5A). However, no changes in lung MMP-2 levels were detected (data not shown). 
Hence, these findings suggest that SP regulates lung MMP-9 levels more than MMP-2 in 
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SP has been shown to directly activate and induce the chemotaxis of numerous immuno-
inflammatory cells, including, neutrophils, macrophages, lymphocytes, monocytes, 
eosinophils and mast cells to release a diverse spectrum of signaling messengers such as 
cytokines, chemokines, and other mediators (O'Connor et al., 2004). After burn injury, 
the heightened inflammation response and ALI characterized by significant neutrophil 
infiltration in the lungs was observed in parallel with higher pro-inflammatory IL-1β, 
TNF-α and IL-6 mRNA and protein production 1h and 8h post burn. Chemokines, MIP-2 
and MIP-1 α were markedly elevated indicating the active role of SP induced 
chemoattractants production in mediating trafficking of inflammatory cells. Treatment 
with L703606 significantly suppressed levels of all these cytokines and chemokines. 
Furthermore, levels of all five molecules were significantly reduced in PPT-A
-/-
 mice; and 
again elevated upon SP injection to PPT-A
-/- 
mice. Thereby, the data demonstrate that SP 
plays an essential role in regulating neutrophil recruitment, as seen in MPO results, 
through chemokines such as MIP-2 and MIP-1 α and that the SP-induced cytokines 
release may further stimulate neutrophils recruited to play an active role in exacerbating 
lung inflammation and injury.  
 
 
Regulation of SP levels is critical in controlling SP-induced inflammation in numerous 
inflammatory diseases, including those of the lung (Di Maria et al., 1998; Roques et al., 
1993). The biological actions of SP are terminated by NEP, and studies show that it is an 
important regulator of SP levels (Lu et al., 1997; Roques et al., 1993). Burn injury 
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induced a significant reduction in NEP activity in lungs of burn-injured WT mice as 
compared to sham-injured WT mice, occurring in parallel with a significant rise in SP 
levels. However, this effect was not observed in PPT-A
-/- 
mice, whereby, the absence of 
SP in sham and burn-injured PPT-A
-/- 
mice, both showed elevated NEP activity. Hence, it 
appears that the presence of SP modulates NEP activity in lungs after burn. This was 
further confirmed when exogenous SP was introduced to sham and burn-injured PPT-A
-/- 
mice, in which NEP activity was significantly lowered in burn-injured PPT-A
-/- 
mice 
compared to sham-injured PPT-A
-/- 
mice. The mechanism behind a loss in NEP activity 
has been reported to be due to its inhibition by oxidation from free radicals (Dusser et al., 
1989). Interestingly, here, SP may serve as an indirect mediator to regulate NEP activity; 
where increased SP levels after burn, induces recruitment of hyper-active inflammatory 
cells, such as neutrophils, which have been shown to regulate NEP (Shipp et al., 1991), 
by releasing excessive oxidants, such as free radicals. Also, with increased tissue 
destruction, the contribution of oxidant release is further increased. Thus, with the 
inhibition of NEP activity early after burn, endogenous SP levels continue to persist at 
high levels, and lung injury is perpetuated.           
 
Matrix metalloproteinases such as MMP-9 are primarily responsible for the turnover and 
degradation of ECM proteins (Atkinson and Senior, 2003). However, their role in 
inflammatory conditions remains unclear. Studies have implicated that excessive levels 
of MMP-9 in inflamed tissues results in excessive proteolysis of tissues, thus, paving the 
way for infiltrating inflammatory cells into tissues, and causing tissue destruction 
(Atkinson and Senior, 2003; Coussens et al., 2000). On the contrary, other studies regard 
MMP-9 as a reparative factor for the re-epithelialization of new proteins along with its 
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ability to degrade non-matrix proteins, including SP (Backstrom and Tokes, 1995), thus 
enhancing wound healing (Betsuyaku et al., 2000; Parks and Shapiro, 2001). Our results 
reveal that MMP-9 levels are markedly increased after burn compared to sham-injured 
WT mice. Despite an increase in MMP-9 levels in burn-injured WT mice, SP levels 
remains significantly high, while lung injury was concurrently intensified. These results 
suggest that SP may have a role in modulating MMP-9 levels after burn, influencing it to 
be more destructive than beneficial in the lungs. Further evidence of SP effect on MMP-9 
levels was demonstrated by removal of SP in burn-injured PPT-A
-/- 
mice which resulted 
in lowered MMP-9 levels; while exogenous administration of SP to burn-injured PPT-A
-/- 
mice restored the MMP-9 lung levels. MMP-9 is known to be induced by pro-
inflammatory cytokines including TNF-α, IL-1 and IL-8 (Ram et al., 2006). After burn, 
SP induces an increase in these cytokines; hence, this up-regulation of cytokines may in-
turn elevate MMP-9 levels, resulting in tissue injury. Additionally, our results indicated 
that burn injury does not alter lung MMP-2 levels (data not shown). Therefore, burn-
induced SP release may work via MMP-9 and not MMP-2 to cause lung tissue injury. A 
significant role of MMP-9 over MMP-2 after burn has also been reported to disrupt 
blood-brain barrier integrity in the rat (Swann et al., 2007). Nonetheless, establishment of 
the exact roles of MMP-9 after burn requires further investigation.      
 
 
In summary, our results demonstrate that SP up-regulates the release and production of 
pro-inflammatory mediators which work to exacerbate systemic inflammation after 
severe local burn injury via NK1R signaling. Inhibition of SP by PPT-A gene deletion 



































































Figure 3.1 Lung mRNA levels of cytokine and chemokine in burn-injured mice 
treated with L703606. The mRNA levels of TNF-α, IL-1β, IL-6, MIP-2 and MIP-1α in 
lung was determined 1h and 8h post burn by semi-quantitative RT-PCR (determined as 
ratio of band densities of TNF-α, IL-1β, IL-6, MIP-2 or MIP-1α to 18S). Mouse 18S 
served as a control. Mice were randomly given L703606 (12mg/kg, i.p.) or vehicle 
(saline) 1h before burn injury. Sham burn mice served as controls. Results shown are the 
mean values ± SEM (n = 6 mice/group at each time point). *, p<0.05 vs sham; **, p<0.01 







































































Figure 3.2 Effect of L703606 pretreatment on lung cytokine and chemokine levels in 
burn-injured mice. Levels of TNF-α (A), IL-1β (B), IL-6 (C), MIP-2 (D) and MIP-1α 
(E) in lung were measured by ELISA at 1h and 8h post burn. Mice were randomly given 
L703606 (12mg/kg, i.p.) or vehicle (saline) 1h before burn injury. Sham-burn mice 
served as controls. Results shown are the mean values ± SEM (n = 6-8 mice/group at 
each time point). *, p<0.05 vs sham; **, p<0.01 vs sham; #, p< 0.05 vs burn + saline; ##, 





























































































































































































































































































Figure 3.3 Reduced pro-inflammatory cytokines and chemokines in burn-injured 
PPT-A
-/-
 mice. Levels of IL-1β (A), TNF-α (B), IL-6 (C), MIP-2 (D) and MIP-1α (E) in 




 mice injected with SP (0.12µg/kg, i.v.) or vehicle 
(saline) 8h after sham or burn injury, were determined by ELISA. Results shown are the 



























































































































































































































































Figure 3.4 NEP activity and expression levels after burn injury. (A) NEP activity at 




 mice injected with SP (0.12µg/kg, i.v.) or 
vehicle (saline) immediately after sham or burn injury. Results shown are the mean 
values ± SEM (n = 4-7 mice per group). *, p<0.05; **, p<0.01. (B) Immunohistochemical 





injected with SP (0.12µg/kg, i.v.) or vehicle (saline) immediately after sham or burn 
injury. Lung sections shown include: sham-injured WT mice (B1), sham-injured PPT-A
-/-
 
mice (B2), sham-injured PPT-A
-/-
 mice injected with SP (B3), burn-injured WT mice 
(B4), burn-injured PPT-A
-/-
 mice (B5) and burn-injured PPT-A
-/-
 mice injected with SP 





























































 mice injected with SP (0.12µg/kg, i.v.) or vehicle (saline) 
immediately after sham or burn injury, were measured by ELISA. Results shown are 





























































































Endothelial cell mediated recruitment and activation of leukocytes is a critical feature of 
the innate immune system in response to injury, which plays a critical role in host defense 
and tissue repair (Nathan, 2002; Witko-Sarsat et al., 2000). However, excessive or 
misdirected leukocyte accumulation in tissue components can lead to an exuberant host 
inflammatory response as seen in many inflammatory diseases (Luster, 1998). This 
focused pathology indicates an essential necessity for identifying the role of mediators 
that instigate effector leukocytes leading to the pathogenesis of inflammatory diseases 
(Luster, 1998). Thereby, blockade of the excessive accumulation of blood-borne effector 
cells in tissues should offer a possibility for effective and selective anti-inflammatory 
therapy (Luster, 1998; Ulbrich et al., 2003; Yonekawa and Harlan, 2005).  
 
SP is known to exert its pro-inflammatory effects via immuno-regulation of numerous 
important inflammatory cells in the circulation (O'Connor et al., 2004). However, the role 
of SP and its receptor, NK1R, in regulating leukocyte numbers and recruitment after 
severe local burn injury remains unclear. As discussed in previous chapters, SP induces 
significant vascular endothelial permeability after burn injury and up-regulates 
chemokines, hence, it was imperative that we investigate the role of SP in regulating the 
circulatory population of leukocyte numbers and its effect on endothelium adhesion 
molecules expressed following severe local burn injury.        
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4.2 Materials and methods 
 
 
4.2.1 Mouse burn injury model  
 
 
For details, see section 2.2.1, page 48.  
 
 
4.2.2 White blood corpuscles-differential count (WBC-DC) 
 
 
Blood was collected by cardiac puncture into EDTA-containing tubes at each time point. 
Samples were analyzed by Celldyne-3700 (Abbott Diagnostics) for WBC-DCs.  
  
 
4.2.3 Adhesion molecules analysis  
 
 
Single-analyte ELISA assays were performed for the measurement of adhesion molecules 
(P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1)) in homogenized lung tissue, ELISA kits, all from R&D 
Systems were used according to the manufacturer‟s instructions. The lower limits of 
detection of the levels of P-selectin, E-selectin, ICAM-1, VCAM-1 were 31.25, 31.25, 
62.5 and 62.5 pg/ml respectively. The ELISA results were reproducible with interassay 
variability of <9.5% and intra-assay variability of <6.5%. Results were then corrected for 
the DNA content of the tissue samples (Labarca and Paigen, 1980) and were expressed as 
picograms per microgram of DNA. 
 
 




For details, see section 2.2.10, page 55.  
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4.3.1 Regulation of leukocyte and platelet cells in the circulatory population by SP-
NK1R signaling following severe local burn injury 
 
 
Previously, our results showed that endogenous levels of SP in plasma were elevated 
after burn injury and that this SP level was significantly lowered by L703606 (Fig. 2.2B). 
Therefore, we wanted to investigate the effect of SP-NK1R signaling on inflammatory 
cells including neutrophils, lymphocytes, monocytes, and as well as platelets in the 
circulation as this would further verify the role of SP in mediating systemic inflammation 
after burn injury.  
 
 
White blood cell, neutrophil, monocyte and lymphocyte absolute numbers along with 
percentage of neutrophil and monocyte subsets all showed significantly higher numbers 
in the circulation after burn injury compared to sham-injured mice (Table 4.1 and 4.2). 
However, administration of L703606 which inhibited SP-NK1R signaling significantly 
lowered the levels of all these inflammatory cells. Additionally, absolute platelet count 
was markedly reduced following burn injury, however, treatment with L703606 resulted 








4.3.2 Burn injury significantly increased the expression levels of adhesion molecules 




Migration of leukocytes into tissues relies on a tightly regulated multi-step adhesion 
signaling cascade involving up-regulation of endothelial selectins and immunoglobulin 
„super-family‟ members (Luster, 1998). A significant increase in P-selectin and E-
selectin (Fig. 4.2A and B) (important for efficient tethering and reducing rolling 
velocities), intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion 
molecule (VCAM)-1 levels (Fig. 4.2C and D) (important for arrest and diapedesis), was 
observed in lungs of burn-injured WT mice compared to sham-injured WT mice. 
Deletion of PPT-A gene significantly reversed the up-regulation of these adhesion 
molecules after burn injury; while administration of exogenous SP restored back their 
levels (Fig. 4.2A to D).  
 
 




Our findings demonstrated the effect of SP-NK1R signaling on the circulatory population 
of immuno-inflammatory cells following severe local burn injury. Neutrophils, 
monocytes, lymphocytes and total white blood cell count were all significantly increased 
at 1h and 8h after burn injury while these effects was inhibited upon administration of 
L703606. Additionally, the trend of endogenous SP concentration in plasma at both 1h 
and 8h exhibited a parallel correlation (Fig. 2.1A and B); as SP was elevated in plasma 
following burn injury, there was a concurrent rise in neutrophils, monocytes, 
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lymphocytes and total white blood cell count. Similarly, upon inhibition of NK1R by 
L703606, SP levels in plasma were markedly lowered and inflammatory cell numbers 
were decreased in the circulation. 
 
Studies have shown that SP modulates neuro-immune effects by numerous signaling 
molecules such as cytokines (Cuesta et al., 2002), chemokines (Yokoyama et al., 1993), 
reactive oxygen species (Serra et al., 1988) and other mediators (O'Connor et al., 2004). 
The mechanism behind the production of these mediators occurs through hyper-activation 
of immuno-inflammatory cells through excessive signaling of SP to the NK1 receptors 
which in times of normal physiological conditions are usually not involved in the cellular 
response to SP (O'Connor et al., 2004). Additionally, results from in vitro studies of 
hematopoiesis further substantiate that SP can hyper-stimulate inflammatory cells. For 
example, SP has been shown to induce bone marrow progenitors of both erythroid and 
myeloid lineages (Rameshwar et al., 1993) which particularly include immune cell 
population subsets such as neutrophils (Iwamoto et al., 1993), eosinophils (Iwamoto et al., 
1993), lymphocytes (Guo et al., 2002), monocytes (Ho et al., 1997), macrophages (Ho et 
al., 1997) and mast cells (Ansel et al., 1993) which all express NK1R on the surface of 
their cells. Hence, in line with these studies, our results suggests that after burn injury, 
significant increases in SP-NK1R complex signaling on numerous immuno-inflammatory 
cells are rapidly stimulated to produce a cascade of pro-inflammatory mediators which 
proceed to intensify ALI.  
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Interestingly, the effect on platelet cells were the opposite, wherein a decline in 
circulating platelets following burn injury was observed but improved to a large extent 
after disruption of SP-NK1R signaling. Studies have demonstrated that platelets have the 
ability store SP and express NK1R (Graham et al., 2004). Furthermore, stimulation of 
platelets isolated from healthy mice by tachykinins resulted in platelet aggregation, while 
inhibition of the NK1R significantly lowered thrombus formation (Jones and Gibbins, 
2008). In a study, platelet numbers were found to decrease following burn injury (Fujimi 
et al., 2006). In our model of burn injury, our results demonstrate a similar trend of a 
significant reduction in circulating platelets. Additionally, we observed that the platelet 
numbers improved profoundly upon blockade of NK1R by L703606 at 1h and 8h 
following burn injury. Published clinical outcomes report that patients with severe burns 
who experience episodes of thrombocytopenia have a higher association of increased 
mortality (George et al., 2001; Takashima, 1997). However, the molecular mechanisms 
behind the reduction in platelet numbers after severe trauma remains unknown (Fujimi et 
al., 2006). Nonetheless, our data suggests that SP may have a role in leading to a decrease 
of platelet numbers and in modulating different cell types after severe local burn injury.  
 
 
Our experiments also revealed an up-regulation of lung endothelial adhesion molecules, 
P-selectin, E-selectin, ICAM-1 and VCAM-1, in burn-injured WT mice. These effects 
were directly reversed in burn-injured PPT-A
-/- 
mice; and when SP was administered to 
burn-injured PPT-A
-/- 
mice, expression of these adhesion molecules were heightened 
again. Interestingly, it is important to note that although selectins are critical for initiating 
the rolling of inflammatory cells in the systemic vasculature; however, their role for 
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transmigration of these cells in lung inflammation is less clear, and studies have shown 
that it depends on the inflammatory stimulus. For example, LPS-induced migration of 
leukocytes into the alveolar space was not prevented by using antagonists against E-, P-, 
and L-selectin (Burns et al., 2001). Furthermore, neutrophil translocation into the lung 
was not affected when E-selectin and P-selectin gene expressions were deleted in mice 
and when L-selectin function was inhibited in a lung inflammatory model induced by 
Streptococcus pneumoniae (Mizgerd et al., 1996). In contrast, all 3 selectins have been 
shown to contribution to lung injury induced by complement or intratracheal deposition 
of IgG complexes (Mulligan et al., 1996), or bacterial LPS (Hayashi et al., 1999). Hence, 
these studies suggest that the involvement of selectins in lung inflammation may be 
stimulus-dependent (Reutershan and Ley, 2004). Thus, in the case of burn-induced ALI, 
we show that burn injury increases P- and E selectin, which is reduced in PPT-A
-/- 
mice, 
suggesting that SP may play a role in modulating their expression after burn.  
 
Therefore, taken together, our findings suggests that excessive production of SP 
instigates not only concurrent increased levels of cellular pro-inflammatory cytokines, 
and chemokines, which shows the active role of SP-induced chemoattractant production 
in mediating trafficking of increased inflammatory cells in the circulation, but as well as 
disruption of endothelial adhesion molecules. By doing so, SP thereby ascertains the 
extravasation, migration and subsequent accumulation of neutrophils in lungs after burn 
injury. Therefore, it is evident that SP is a critical player involved in many key events of 
the systemic inflammatory cascade following burn injury.  
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 Anti-coagulated whole blood at 1h and 8h post-burn was analyzed for absolute cell 
numbers. Mice were randomly given L703606 (12mg/kg, i.p.) or vehicle (saline) 1h 
before burn. n = 8-12 mice per group per time point. Results shown are the mean values ± 
SEM. 
b 
p<0.01, Burn + saline vs sham                                                                                                                    
c
 p<0.01, Burn + saline vs Burn + L703606 (12mg/kg)                                                                                                                                             
d

























1h post-burn  
Normal                                         
Sham                                            
Burn + Saline                               
Burn + L703606 (12mg/kg)  
8h post-burn  
White blood cells Neutrophils Monocytes 
1.27 ± 0.10       
1.33 ± 0.09     
2.71 ± 0.41b  
1.56 ± 0.12c 
0.61 ± 0.03       
0.63 ± 0.04    
1.16 ± 0.10b  
0.71 ± 0.05c 
0.02 ± 0.01       
0.02 ± 0.01    
0.07 ± 0.02b   
0.03 ± 0.01d 
0.67 ± 0.07       
0.68 ± 0.08    
1.68 ± 0.26b  
0.83 ± 0.09c 
Animal group, by time 
following injury 
Lymphocytes 
Normal                                         
Sham                                            
Burn + Saline                               
Burn + L703606 (12mg/kg)  
0.60 ± 0.04       
0.59 ± 0.04    
2.57 ± 0.18b   
1.69 ± 0.16c 
0.02 ± 0.01       
0.02 ± 0.01    
0.05 ± 0.01b   
0.03 ± 0.02d 
0.67 ± 0.07       
0.62 ± 0.06    
1.72 ± 0.20b  
0.59 ± 0.09c 
1.29 ± 0.09       
1.35 ± 0.10     
4.20 ± 0.21b  
3.22 ± 0.13c 
Absolute cell numbers, x 103/µl, mean ± SEM 
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 Anti-coagulated whole blood at 1h and 8h post-burn was analyzed for percent 
neutrophils, monocytes and lymphocytes. Mice were randomly given L703606 (12mg/kg, 
i.p.) or vehicle (saline) 1h before burn. n = 8-12 mice per group per time point. Results 
shown are the mean values ± SEM.  
b
 p<0.01, Burn +  saline vs sham                                                                                                                                                                                                                        
c
 p<0.05, Burn + saline vs sham                                                                                                                   
d
 p<0.001, Burn + saline vs Burn + L703606 (12mg/kg)                                                                      
e

























Lymphocytes Neutrophils Monocytes 
Normal                                          
Sham                                            
Burn + Saline                               
Burn + L703606 (12mg/kg)  
23.44 ± 1.05       
28.51 ± 2.48    
56.15 ± 1.32b  
41.15 ± 2.11d 
8h post-burn  
Normal                                          
Sham                                            
Burn + Saline                               
Burn + L703606 (12mg/kg)  
22.97 ± 0.97       
26.48 ± 2.02    
77.56 ± 5.31b 
61.12 ± 4.27e 
0.96 ± 0.17        
0.91 ± 0.25    
2.15 ± 0.33c  
1.28 ± 0.24e 
0.87 ± 0.21        
0.92 ± 0.17    
2.13 ± 0.42b 
1.10 ± 0.43d 
57.92 ± 3.26       
62.00 ± 3.65    
39.91 ± 3.17b  
51.45 ± 2.44e 
63.57 ± 2.80       
67.12 ± 2.79    
23.75 ± 6.72b  
30.24 ± 4.00 
Percent leukocyte subset, x 103/µl, mean ± SEM Animal group, by time 
following injury 
























Figure 4.1. Role of SP-NK1R signaling on platelet count following burn injury. 
Platelet counts were determined at 1h and 8h post burn. Mice were randomly given 
L703606 (12mg/kg, i.p.) or vehicle (saline) 1h before burn injury. Sham burn mice 
served as controls. Results shown are the mean values ± SEM (n = 8-12 mice/group at 

















































































































































































































































































































































































Figure 4.2 Effect of PPT-A gene deletion on expression of adhesion molecules after 
burn injury. Levels of P-selectin (A), E-selectin (B), ICAM-1 (C) and VCAM-1 (D) in 




 mice injected with SP (0.12µg/kg, i.v.) or vehicle 
(saline) 8h after sham or burn injury, were measured by ELISA. Results shown are the 











































Breathing is an extraordinarily steadfast and consistent behavior in vertebrates that 
regulates blood gas exchange, pH, temperature and diverse activities including sleep, 
physical exercise, pregnancy and ageing (Feldman and Del Negro, 2006). Impairment of 
the pulmonary and cardiovascular systems are the major causes of breathing disorders; 
however, it is important to note that abnormal functioning of the neutral control over 
breathing also has a major impact in respiratory diseases (Feldman and Del Negro, 2006). 
For example, mortality due to central respiratory arrest while sleeping is frequently 
encountered in patients with Parkinson‟s disease, multiple systems atrophy, amyotrophic 
lateral sclerosis and in the elderly (Feldman and Del Negro, 2006).  
 
Studies have reported evidences on how the nervous system could influence respiratory 
function, of which, one connection is through neuropeptides. Several neuropeptides 
including SP (Chen et al., 1990; Chen et al., 1988; Gray et al., 2001), somatosatin (Kalia 
et al., 1984), thyrotropin-releasing hormone (McCown et al., 1986) and bombesin 
(Hedner et al., 1985) were shown to have significant effects on modulating breathing 
function when locally applied in the brain stem region.  However, none have investigated 
the effect of endogenous SP on lung function following severe local burn injury. 
Furthermore, as discussed in previous chapters, SP was observed to significantly induce 
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remote ALI after burn, thus, for this reason, we were interested to investigate whether SP 
is concurrently involved in affecting respiratory function after burn injury.  
 
 








For details, see section 2.2.1, page 48.  
 
5.2.2 Measurement of lung function  
 
 
Eight and twenty-four hours after burn injury, in vivo respiratory patterns in unrestrained, 
conscious mice using a whole-body plethysmography system were measured repeatedly 
(Buxco Electronics, Troy, NY) (DeLorme and Moss, 2002). The whole-body 
plethysmograph chamber utilizes a barometric analysis technique that compares the 
pressure difference between the animal chamber and a reference chamber to measure 
airway physiological parameters. Resulting changes in pressure/volume readings in 
inspiration and expiration reflect the pulmonary function of the animal. After chamber 
calibration to ambient pressures and temperature, signals were recorded, and various 
respiratory variables were calculated using the manufacturer software. Before recording, 
mice were placed individually into the main chamber and allowed to acclimate for 5 mins. 
Mean respiratory variables were then calculated from 15 mins recordings of continuous 
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respiratory behavior (Gray et al., 2001). In vivo parameters obtained include: Ve (ml/min), 
RR (breaths/min), VT (ml), PEF (ml/s), PIF (ml/s), Ti (s) and Te (s).  
 
5.2.3 Measurement of SP, MPO activity and histological examination 
 
For details, see sections 2.22, 2.23 and 2.25 for SP measurement, MPO activity, and 















5.3.1 Progressive improvement of lung function in burn-injured mice lacking PPT-A 
gene products over 8h and 24h 
 
Mammalian respiratory rhythm generation is controlled critically by central neural 
modulation (Feldman and Del Negro, 2006). Throughout the central nervous system, SP 
is widely distributed, however, more importantly; the presence of SP has been shown to 
be intensified particularly in areas of the body involved in the control of autonomic 
function, such as respiration (Bongianni et al., 2008). Not surprisingly, the excitatory 
effects of SP on respiratory activity have been documented (Chen et al., 1990; Gray et al., 
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2001; Marano et al., 1988). Therefore, we were interested to determine the effect of PPT-
A gene deletion in unrestrained conscious mice and subsequent injection with exogenous 
SP on breathing rhythm after burn injury over an extended time at 8h to 24h, using whole 
body plethysmography.  
 
Burn injury augmented significant reductions in minute ventilation (VE) owing to 
concomitant decreases in respiratory rate (RR) and tidal volume (VT) in WT mice 
compared to sham-injured mice at 8h and 24h (Fig. 5.1A to C). VE is defined as the 
volume of gas that moves in and out of the lungs in one minute and is calculated by 
multiplying VT and RR (Guyton and Hall, 2000). Deletion of PPT-A gene in burn-injured 
mice significantly elevated RR at both 8h and 24h; however, this did not increase VT at 
8h but only at 24h compared to burn-injured WT mice (Fig. 5.1B and C). Without the 
maintenance of VT, although there was a rise in RR at 8h, burn-injured PPT-A
-/-
 mice did 
not show improvement in VE at 8h. However, by 24h time, VT levels begin to increase 
significantly compared to sham-injured PPT-A
-/-
 mice along with RR, and as such, VE 
improved significantly back to levels similar to sham PPT-A
-/-
 mice (Fig. 5.1A to C). 
Injection of exogenous SP to burn-injured PPT-A
-/-
 mice, significantly blunted RR, VT 
and VE compared to sham-injured PPT-A
-/-
 mice administered SP at 8h and 24h; however, 
when compared to burn-injured PPT-A
-/-
 mice alone, burn-injured PPT-A
-/-
 mice injected 
with SP showed only improved RR at 8h, and by 24h, all three respiratory responses, RR, 
VT and VE had significant improvements.    
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Measurements of peak expiratory flow (PEF) are of value in identifying air flow 
limitations (Quanjer et al., 1997). Diseases that narrow the airways will have a more 
profound effect on limiting the PEF and lengthening the time required for exhalation 
(Wyka, 2002). After burn injury, WT mice exhibited a significant drop in PEF and 
lengthening of expiratory time (Te) compared to sham-injured WT mice (Fig. 5.1D and 
E). Concurrently, a similar decrease in peak inspiratory flow (PIF) and increase in 
inspiratory time (Ti) was seen (Fig. 5.1F and G). Deletion of PPT-A gene resulted in a 
reduced Te and Ti at both 8h and 24h after burn (Fig. 5.1E and G). A reversal was seen at 
both time points, where burned-injured PPT-A
-/-
mice injected with SP had lengthened Te 
and Ti compared to burned-injured PPT-A
-/-
 mice alone and sham-injured PPT-A
-/-
 mice 
treated with SP. PEF and PIF levels in burn-injured PPT-A
-/-
 mice were not increased at 
8h but rose up significantly at 24h compared to burned-injured WT mice (Fig. 5.1D and 
F); injection of SP to burn-injured PPT-A
-/- 
mice reversed the response at 24h, where PEF 
and PIF were significantly diminished, close to burn-injured WT mice levels.     
 
5.3.2 Significant disruption of lung function correlated with exacerbated ALI and 
SP elevation at 24 hours   
 
The changes in lung function at 24h after burn had instigated us to confirm if there was a 
direct and opposite concurrent lung damage in these same mice, similar to the effects 
seen at 8h. MPO activity and lung histology revealed increased neutrophil infiltration and 
damage in burn-injured WT mice; these effects were significantly diminished in burned 
PPT-A
-/-
 mice; while burn-injured PPT-A
-/- 
mice injected with SP again showed a shift 
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back towards lung damage (Fig. 5.2A and B). Levels of SP in lung and plasma were also 
elevated at 24h after burn in WT mice (Fig. 5.2C and D).    
 




Pulmonary complications in burn patients are well reported, and frequently lead to the 
development of acute lung injury or lung failure, even when the lungs have not sustained 
direct burn injury (Kramer et al., 2002; Turnage et al., 2002). Therefore, it was 
imperative that we test the hypothesis of whether SP affects lung function in mice after 
burn injury using whole body plethysmography. Our data shows that concurrent with 
increased lung damage and elevated SP levels at 8h and 24h post-burn, lung function was 
significantly affected in all seven respiratory parameters; VE, VT, RR, PEF, PIF, Te and 
Ti; after burn injury in WT mice. Studies have shown that intraventricular injections of 
SP caused marked increases in RR and VT in cats and rabbits (Von Euler US and 
Gaddum JH, 1931). Intracerebroventricular injections of SP and microinjections of SP 
into the ventrolateral medulla also augmented minute ventilation owing to increases in VT 
in rats (Chen et al., 1990; Hedner et al., 1984). In our burn injury model, ablation of SP 
by genetic deletion of PPT-A gene, showed a rescue in VE, VT and RR, closer to sham-
injured mice levels by 24h time; while re-introduction of SP by i.v. administration in the 
tail vein of PPT-A
-/- 
mice immediately after burn, reversed these effects.  
 
Inspiration is an active procedure that requires work done by contraction of the 
diaphragm and respiratory muscles, which relies directly on the ability to expand the 
lungs against elastic recoil, air flow resistance and tissue resistance of lung and thorax 
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(Guyton and Hall, 2000). Expiration in healthy lungs is exclusively a passive procedure, 
and occurs in resting state, it is mediated by relaxation of the diaphragm and elastic recoil 
of lung and thorax, however, in the event of respiratory distress is actively maintained by 
respiratory muscles (Guyton and Hall, 2000). Exertion of respiratory muscles during 
exhalation becomes apparent when parameters such as PEF are decreased and Te is 
lengthened (Guyton and Hall, 2000; Wyka, 2002). Burn-injured mice exhibited such an 
effect at 8 and 24h post-burn; PPT-A
-/- 
mice displayed a rescue by 24h time; while levels 
were again disrupted upon SP challenge. PIF and Ti also demonstrated similar effects; 
thus, these data indicate that large inspiratory efforts had to be done by the lungs after 
burn injury to compensate for a higher need of oxygen followed by prolonged expiration.   
 
The influence of SP in respiratory function extends beyond the lungs. It is established 
that the rhythm underlying breathing depends critically on neurons in the preBötzinger 
complex (preBötC), a region of the medullary oblongata proposed to contain the kernel of 
networks for rhythm generation (Smith et al., 1991). Interestingly, it was found that 
neurons in the preBötC express intense NK1R immuno-reactivity (Gray et al., 2001). 
Studies show that the stimulatory effect of microinjections of SP into preBötC, resulted in 
modulation of respiratory rhythm (Chen et al., 1990). While others showed that regional 
ablation of preBötC NK1R expressing neuron, severely disrupted breathing pattern in 
conscious rats, using whole body plethysmography (Gray et al., 2001). Similar results 
were also confirmed in larger animals such as goats (Wenninger et al., 2004). Clearly, 
these studies indicate that SP and its receptor are important for maintenance of normal 
breathing. Therefore, our results, just as these studies have shown, point to an obvious SP 
mediated neural-respiratory communications after burn injury. Our data demonstrate that 
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along with excessive production of SP in the lungs and plasma, lung function is 
significantly disrupted after burn injury in mice and therefore shows its importance in 













































































































































Figure 5.1 Progressive lung function responses after burn injury. Respiratory 
responses of Ve (A), RR (B), TV (C), PEF (D), Te (E), PIF (F) and Ti (G) were recorded 




 mice injected with SP (0.12µg/kg, 
i.v.) or vehicle (saline) 8h after sham or burn injury, using whole body plethysmography. 
Results shown are the mean values ± SEM (n = 10-21 mice per group per time point). 
Mean values were calculated from 15mins of continuous respiratory behavior. *, p<0.05 
comparing burn + saline (WT) vs sham + saline (WT); §, p<0.05 comparing burn + saline 
(PPT-A
-/-
) vs burn + saline (WT); †, p<0.05 comparing burn + SP (PPT-A-/-) vs sham + 
SP (PPT-A
-/-
); #, p<0.05 comparing burn + saline (PPT-A
-/-



























































































































































































































































































Figure 5.2 ALI assessment correlated with augmented SP levels in plasma and lungs 





injected with SP (0.12µg/kg, i.v.) or vehicle (saline) 24h after sham or burn injury. 
Results shown are the mean values ± SEM (n = 5-6 mice per group). *, p<0.05; **, 
p<0.01. (B)  Histopathological evaluation (H&E staining) at 24h of lung PMN infiltration 




 mice injected with SP (0.12µg/kg, i.v.) or 
vehicle (saline) immediately after sham or burn injury. Sham burn mice served as 





 mice injected with SP (B3), burn-injured WT mice (B4), 
burn-injured PPT-A
-/-
 mice (B5) and burn-injured PPT-A
-/-
 mice injected with SP (B6). (n 
= 6 mice per group). Bars, 20µm. (C-D) SP levels in plasma (C) and lung (D) of WT 
mice 24h after sham or burn injury. Results shown are the mean values ± SEM (n = 7-9 





















Chapter VI   Effect of SP on extracellular signal-regulated kinase 
(ERK)-NFκB pathway and its association with pulmonary 
cyclooxygenase-2 and prostaglandin E metabolite expression  







The molecular mechanisms by which SP elicits its pro-inflammatory effects have been 
shown to involve SP binding to its G protein-coupled receptor, NK1R, which then signals 
via the classical MAP kinase and NF-κB pathway (Chang et al., 2009; Williams et al., 
2007). Activation of the key transcription factor, NF-κB, is well known to lead to the up-
regulation of numerous mediators involved in inflammatory diseases, including cytokines, 
chemokines, cell adhesion molecules, acute phase proteins and important enzymes such 
as cyclooxygenase (COX)-1 and -2 (Barnes and Karin, 1997; Krakauer, 2004; Tak and 
Firestein, 2001; Yamamoto and Gaynor, 2001). COX-1 has the characteristics of a 
“housekeeping enzyme” as it is constitutively expressed in numerous cells. Its 
endogenous levels are found to play an important role in normal physiological functions, 
including regulation of vascular activity and maintenance of gastrointestinal function 
(Dubois et al., 1998). In contrast, COX-2 is an inducible enzyme stimulated by numerous 
molecules including mitogens, cytokines, oxidants and microbial products (Krakauer, 
2004). COX-2 has been shown to be the primary isoform of the two enzymes responsible 
for the synthesis of prostanoid mediators of pain and inflammation, such as prostaglandin 
E2 (PGE2) (Krakauer, 2004). Studies have demonstrated PGE2 to be a potent mediator of 
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pulmonary edema in acute lung injury (ALI) (Park and Christman, 2006). Increased 
COX-2 gene expression was also found in-conjunction with elevated ALI in mice while 
inhibition of COX-2 at the transcriptional and protein levels attenuated ALI in an acid 
model of ALI and carrageenan induced pleurisy model (Cuzzocrea et al., 2002; Ohara et 
al., 1998). Additionally, PGE2 has been shown to exert significant vasodilation, pain and 
immune system dysfunction after burn injury (Hahn and Gamelli, 2000; Ogle et al., 1993; 
Schwacha et al., 1999). Significant levels of systemic prostaglandin levels were found in 
the plasma of severely burn-injured patients (Liu et al., 1996); while macrophages 
isolated from burn-injured experimental animals produced increased PGE2 levels 
(Schwacha et al., 2002). More importantly, selective inhibition of COX-2 attenuated 
acute inflammation and improved immune function after burn injury (Grbic et al., 1991; 
Hahn and Gamelli, 2000).              
 
Earlier in this study, we have shown that pre-treatment in burn-injured WT mice with L-
703606, a potent and specific antagonist to NK1R, resulted in blockage of SP-NK1R 
signaling, which significantly lowered the release of lung neutrophils, pro-inflammatory 
cytokines and chemokines along with reduced cells counts of neutrophils, monocytes, 
and lymphocytes in the circulation (described in chapter II, III and IV). Hence, after burn 
injury, it is clear that SP works by activating NK1R, known to be present on lung cells 
and immune cells, to elicit its downstream pro-inflammatory effects. However, the 
downstream signaling pathway by which SP-NK1R signaling leads to in the lungs 
following severe local burn injury remains unknown. Furthermore, the association of 
COX-2 and PGE2 with SP-related lung inflammatory responses after burn injury is not 
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known. Therefore, in the present study we aimed to investigate whether SP-NK1R 
signaling regulates ALI after burns via the ERK-NF-κB pathway, which is a major 
component of the MAP kinase pathways involved in inflammation. Additionally, we 
were interested to elucidate the effects of SP-NK1R signaling on COX-2 and PGE2 
expression levels in the lung, and the contribution of COX-2 and PGE2 to ALI after burn. 
Therefore, to assess the role of COX-2 in ALI after burn injury, we used a potent and 
selective inhibitor of COX-2, parecoxib (Padi et al., 2004; Talley et al., 2000). It belongs 
to a family of medicines called Coxibs which work to relieve pain and inflammation. 
Parecoxib is a water-soluble prodrug of valdecoxib and is the first COX-2 specific 
inhibitor used for parenteral administration. At therapeutic doses, parecoxib does not 
appear to affect COX-1, which is crucial for maintaining normal function in the stomach 
and blood (Teagarden and Sandeep, 2007).  
 
 
6.2 Materials and methods  
 
 
6.2.1 Mouse burn injury model  
 
 
For details, see section 2.2.1, page 48.  
 
6.2.2 Time course study of lung tissue SP levels, COX-2 expression and activity 
levels, ERK1/2 activation and IκBα phosphorylation and degradation after burn 
injury 
 
In separate groups, some WT mice were sacrificed at 0min, 30min, 1h, 2h, 4h and 8h 
after sham or burn injury. Lung samples were collected and stored at –80 °C for 
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subsequent measurements of SP levels, COX-2 expression and activity levels, ERK1/2 
activation and IκBα phosphorylation and degradation. A final time point of 2h after 
induction of sham or burn injury was chosen for all future experiments.  
 
 
6.2.3 Effect of parecoxib, a selective COX-2 inhibitor, in burn-induced ALI 
 
Parecoxib (Dynastat), a potent and selective COX-2 inhibitor specifically developed for 
parenteral administration (Padi et al., 2004; Talley et al., 2000; Teagarden and Sandeep, 
2007), was supplied in glass vials (40mg/vial, Pfizer) and dissolved in 0.9% sterile 
normal saline immediately before use. In a separate group, WT mice were treated with 
dose dependent concentrations of parecoxib (0, 5, 10, 20 and 30mg/kg, administered i.v) 
or vehicle (saline), 20min after sham or burn injury. A final dose of 30mg/kg of 
parecoxib, administered i.v., was chosen for all future experiments. In a another group, 
PPT-A
-/-
 mice injected with SP (0.12μg/kg, i.v.) or vehicle (saline) immediately after 
sham or burn injury, were subsequently administered parecoxib (30mg/kg, i.v.) 20min 
later.        
 
 




PD98059, a potent and selective antagonist of MEK-1, which is the upstream kinase of 
ERK1/2 (10mg/kg, i.p.; Calbiochem, USA) was dissolved in vehicle (dimethyl 
sulfoxide/0.9%NaCl [1:50]; 5ml/kg, i.p.) and administered to WT or PPT-A
-/-
 mice 1h 
before sham or burn injury as previously described (Minutoli et al., 2005; Tamaoki et al., 
2004; Zhang et al., 2008; Zhang and Dong, 2005). Notably, we have shown previously 
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that the concentration of DMSO used in the vehicle to dissolve PD98059 has no effect on 
ERK kinase activation in the lungs (Zhang et al., 2008).   
 
 
6.2.5 Effect of Bay 11-7082, a selective inhibitor of NF-κB, in burn-induced ALI 
 
 
Bay 11-7082 (20mg/kg, i.p., Calbiochem), a specific inhibitor of NF-κB (Pierce et al., 
1997), or vehicle (0.5% v/v DMSO in 0.9% sterile saline) was administered 30min before 
sham or burn injury in WT or PPT-A
-/-
 mice. The dose of Bay 11-7082 used was chosen 
based on previous studies (Zhang et al., 2007). The final DMSO concentration used did 
not have any effect in our experiments and in other studies (Malaver et al., 2009; Strohm 
et al., 2000; Tamaoki et al., 2004).  
 
6.2.6 Measurement of SP, MPO activity, histological examination, cytokine and 
chemokine analysis 
 
For details, see sections 2.22, 2.23, 2.25 for SP measurement, MPO activity and 
histological examination respectively, page 50 to 52. For cytokines (IL-1β, IL-6 and 
TNF-α) and chemokines (MIP-2 and MIP-1α) analysis, see section 3.2.3, page 86.  
 
6.2.7 Measurement of COX-2 activity 
 
COX-2 activity was measured according to the manufacturer‟s instructions (Cayman 
Chemicals). Briefly, lung samples were homogenized in ice-cold lysis buffer (0.1M Tris-




centrifuged (10,000 x g, 15min, 4°C), the supernatants collected and 
stored at -80ºC for subsequent analysis with commercially available COX activity assay 
kit (Cayman Chemicals). The results were corrected for the DNA content of the
 
tissue 
sample and expressed as fold increase over control
 
(Labarca and Paigen, 1980) 
 
6.2.8 Measurement of PGE metabolite (PGEM) levels  
 
Lung PGEM levels were determined by ELISA kits (Cayman Chemicals), according to 
the manufacturer‟s instructions. The results were corrected for the DNA content of the 
tissue sample and expressed as fold increase over control
 
(Labarca and Paigen, 1980) 
 
6.2.9 Preparation of nuclear extract and measurement of NF-κB activation  
 
Nuclear extracts from lung (50mg) were prepared by using Nuclear Extraction Kit as 
described by the manufacturer (Active Motif, Tokyo, Japan). Protein concentrations in 
nuclear extracts were determined using Bradford assay (Bio-Rad, CA, USA). To monitor 
NF-κB activation in lung tissues, we used a TransAM NF-κB p65 Transcription Factor 
Assay Kit (Active Motif, Tokyo, Japan). The kit consists of a 96-well plate, into which 
oligonucleotide containing the NF-κB consensus site (5‟-GGGACTTTCC-3‟) is bound. 
The active form of NF-κB in the nuclear extract specifically binds to this consensus site 
and is recognized by a primary antibody specific for the activated form of p65 of NF-κB. 
A horseradish peroxidase-conjugated secondary antibody provides the basis for the 
colorimetric quantification. The absorbance of the resulting solution was measured 2 min 
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later (450nm with a reference wavelength of 655 nm), using a 96-well microplate reader 
(Tecan Systems Inc., San Jose, CA, USA). The wild-type consensus oligonucleotide is 
provided as a competitor for NF-κB binding in order to monitor the specificity of the 
assay. Results were expressed as fold increase over the control group. 
 
6.2.10 Western immunoblot 
 
For details, see section 2.2.8, page 53. The primary antibodies used for detection for 
proteins of interest include: rabbit polyclonal anti-COX-2 (Cayman Chemicals; 1: 1000 
dilution), rabbit anti-IκBα, phospho-IκBα, ERK1/2, phospho-ERK1/2 (Cell Signaling 





For details, see section 2.2.10, page 55. 
 
 








Endogenous lung SP levels were significantly increased as early as 30min after burn 
injury compared to WT mice at 0min post burn, which were not induced with burn injury 
(Fig. 6.1A). Moreover, the SP levels continued to remain significantly elevated at 1h, 2h, 
4h, and up to 8h after burn injury. In an attempt to correlate if there were also 
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simultaneous changes in lung COX-2 levels as there were in SP levels after burn injury, 
we performed western blot analysis for the same time points to evaluate the lung 
expression levels of COX-2 in WT mice. Our results revealed a concurrent increase in 
COX-2 levels in a time dependent manner which peaked at 0.5h to 2h post burn (Fig. 
6.2A). Additionally, a similar time dependent profile was observed in lung COX-2 
activity levels over the same time points, with the highest level of COX-2 activity 
peaking significantly at 2h post burn compared to WT mice at 0min post burn (Fig. 6.2B). 
Therefore, these results show that burn injury induces a concomitant and significant 
overproduction of both SP and COX-2 in the lungs. Notably, the levels of both SP and 
COX-2 are prominently expressed at 2h post burn (Fig. 6.1 and 6.2), therefore, this time 
point was chosen for all future experiments.      
 




To assess the severity of COX-2 mediated ALI after burn injury, we examined the effect 
of parecoxib on lung myeloperoxidase activity, which is an important index of lung 
neutrophil accumulation. Parecoxib was administered therapeutically at 20mins post burn 
to burn-injured WT mice in a dose dependent manner of 0, 5, 10, 20 and 30mg/kg 
intravenously, and MPO activity was subsequently measured at 2h post burn. The results 
reveal that only the dose of 30mg/kg of parecoxib markedly lowered lung MPO activity, 
while no significant inhibition was observed with all the other lower doses (Fig. 6.3). 
Therefore, the dose of 30mg/kg parecoxib was used for all future experiments.  
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6.3.3 Blockade of SP-NK1R signaling and COX-2 expression significantly protects 
against burn-induced ALI 
 
The severity of ALI is clearly characterized by the invasion of neutrophils into the lungs 
(Wheeler and Bernard, 2007). Following burn injury, lung MPO levels were markedly 
increased which correlated with augmented SP and COX-2 expression levels in WT mice 
(Fig. 6.4A). Notably, the MPO activity levels were significantly attenuated in burn-
injured WT mice treated with L703606, a specific NK1R antagonist at a dose of 12mg/kg, 
i.p., 1h before burn injury, and 30mg/kg of parecoxib, i.v., 20mins post burn, suggesting 
that SP-NK1R signaling and COX-2 play a pivotal role in modulating ALI after burn (Fig. 
6.4A). Additionally, to further confirm our findings, we used mice deficient in the 
preprotachykinin-A (PPT-A) gene, which encodes for SP, to investigate the link between 
SP, COX-2 and ALI after burn injury. Our results showed that the heightened MPO 
activity levels observed in burn-injured WT mice was significantly abrogated in burn-
injured PPT-A
-/-
 mice, indicating that overproduction of SP can lead to a significant 
increment in MPO activity levels after burn. Consistent with these findings, the drop in 
MPO activity levels in burn-injured PPT-A
-/-
 mice was significantly reversed in burn-
injured PPT-A
-/-
 mice injected with exogenous SP (Fig. 6.4A). Moreover, lower levels of 
MPO activity were again restored upon treatment with parecoxib in burn-injured PPT-A
-/-
 
mice injected with exogenous SP, thereby, confirming the important role of SP and COX-
2 in mediating lung neutrophil infiltration after burn injury (Fig. 6.4A). Subsequently, we 
further extended our investigation by performing histopathological examination at 2h 
post burn. Consistently, alleviated alveolar congestion, lowered leukocyte infiltration, 
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alveolar septal wall thickness and interstitial edema were observed in WT mice treated 
with L703606 (Fig. 6.4B5) and parecoxib (Fig. 6.4B6) after burn and in burn-injured 
PPT-A
-/-
 mice (Fig. 6.4B10) compared to burn-injured WT mice (Fig. 6.4B4). Burn-
injured PPT-A
-/-
 mice injected with SP (Fig. 6.4B11) again demonstrated severe ALI 
similar to burn-injured WT mice. In contrast, burn-injured PPT-A
-/-
 mice injected with SP 
showed significant protection from ALI and restoration of normal lung histoarchitecture 
after treatment with parecoxib at 2h post burn (Fig. 6.4B12). Notably, in both MPO 
activity and histology, all sham-treated mice showed basal levels, particularly in sham-
injured WT mice treated with L703606 and parecoxib, and in sham-injured PPT-A
-/-
 mice 
injected with SP which were subsequently treated with parecoxib at 20mins post burn. As 
such, after confirming that the doses of 12mg/kg of L703606 and 30mg/kg of parecoxib 
had no adverse effect on lung neutrophil infiltration and histopathology of sham-injured 
WT or PPT-A
-/-
 mice, these sham-injured mice were not included in other experiments. 
Therefore, collectively, these results show that the absence of SP and inhibition of SP-
NK1R signaling and COX-2 are critical in resolving ALI after burn.    
 
6.3.4 Inhibition of SP-NK1R signaling and COX-2 up-regulation greatly impairs 
cytokines and chemokines production following burn injury 
 
Evaluation of pro-inflammatory cytokines, IL-1β, TNF-α and IL-6 and chemokines, MIP-
2 and MIP-1α showed a marked rise in all of their levels after burn in WT mice (Fig. 6.5). 
Consistent with MPO and histology results, burn-injured WT mice treated with L703606 
and parecoxib, along with burn-injured PPT-A
-/-
 mice showed an evident rescue in 
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production of IL-1β, TNF-α, IL-6, MIP-2 and MIP-1α, known to exert profound effects 
in numerous inflammatory diseases. Importantly, levels of all five cytokines and 
chemokines were observed to be amplified in burn-injured PPT-A
-/-
 mice injected with 
SP; while blockage of COX-2 with parecoxib in burn-injured PPT-A
-/-
 mice injected with 
SP significantly reverted back their levels to become lower again (Fig. 6.5).        
 
6.3.5 Activation of SP-NK1R signaling and COX-2 expression levels leads to the 
production of PGE2 metabolite (PGEM) following burn injury 
 
The enhanced lung COX-2 expression levels observed in our results, together with the 
evident reduction in MPO activity after administration of parecoxib in burn-injured WT 
mice, instinctively lead us to examine lung PGE2 levels after burn. PGE2 is known to be 
rapidly metabolized in the lungs (Piper, 1974; Piper et al., 1970; Wyllie et al., 1969), as 
such, measurement of PGEM is necessary to provide a reliable estimate of actual PGE2 
production (Bothwell et al., 1982; Granstrom et al., 1980; Maclouf et al., 1987). As 
expected, PGEM levels were heightened after burn, which correlated with augmented 
COX-2 expression levels in WT mice (Fig. 6.6A). Notably, treatment with L703606 and 
parecoxib significantly inhibited PGEM levels at 2h post burn. Furthermore, when burn-
injured WT mice was compared to burn-injured PPT-A
-/-
 mice, an obvious reduction in 
PGEM levels was observed in burn-injured PPT-A
-/-
 mice. However, upon administration 
of exogenous SP to burn-injured PPT-A
-/-
 mice, this effect was significantly reversed. 
More importantly, treatment with parecoxib abolished the elevated PGEM levels in burn-
injured PPT-A
-/-
 mice injected with SP (Fig. 6.6A). Taken together, our results show 
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compelling evidence that SP-NK1R signaling and COX-2 are important in influencing 
the extent of PGEM production after burn injury. This also indicates that SP-NK1R 
signaling and COX-2 up-regulation occurs upstream of PGEM production after burn 
injury, thereby showing that SP has the ability to initiate the up-regulation of key 
inflammatory mediators such as PGE2 that can contribute extensively to the severity of 
ALI after burn.  
 
6.3.6 Time course study of lung ERK1/2 activation, phosphorylation and 
degradation of IκBα levels following burn injury 
 
 
To investigate the signaling mechanisms leading to a rise in COX-2 expression levels in 
the lungs and elevated ALI following burn injury, we evaluated the ERK-NF-κB pathway, 
an important signal transduction pathway involved in regulating numerous inflammatory 
responses (Kyriakis and Avruch, 2001). Since the levels of SP and COX-2 were 
significantly increased over 30min, 1h, 2h, 4h and 8h as seen earlier in this study, we 
were also interested to determine whether the kinetics of ERK1/2 phosphorylation as well 
as IκBα phosphorylation and degradation in the lungs were affected over the same time 
points following burn injury. In agreement with changes over time of increased 
pulmonary SP and COX-2 expression levels, the phosphorylation of ERK1/2 showed 
marked increases from 30min to 8h post burn compared to 0min (Fig. 6.7A). Furthermore, 
evaluation of IκBα phosphorylation showed a progressive increase over time with a 
significant rise at 2h post burn (Fig. 6.7B). Likewise the content of IκBα was reduced in a 
time dependent manner with a significant occurrence of degradation obtained at 2h post 
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burn (Fig. 6.7C). Taken together, these data show that burn injury induces activation of 
the ERK-NF-κB pathway which was observed to take place with concomitant increases 
in SP and COX-2 pulmonary levels over time. As such, this verified that further 
investigation on the ERK-NF-κB pathway following burn injury was imperative; 
therefore, we focused on the cellular changes of these molecules at 2h post burn for the 
rest of this study.             
     
6.3.7 Induction of SP-NK1R signaling and ERK1/2 pathway markedly augmented 
COX-2 expression levels after burn injury 
 
To determine the critical link between SP-NK1R signaling and ERK1/2 activation 
leading to changes in COX-2 expression levels, we performed western blot analysis using 
L703606 and PD98059, a potent and selective antagonist of MEK-1, administered at a 
dose of 10mg/kg, 1h before burn injury. A significant increment in COX-2 expression 
levels were observed following burn injury in WT mice at 2h post burn (Fig. 6.8A). Of 
particular importance was that this effect was abolished in burn-injured WT mice treated 
with both L703606 and PD98059 (Fig. 6.8A). Thus, these results show evidently that SP-
NK1R and ERK1/2 signaling significantly influences the expression levels of COX-2 in 
the lungs after burn injury, and further imply that SP-NK1R and ERK1/2 signaling occurs 
upstream of COX-2 expression. Additionally, usage of burn-injured PPT-A
-/-
 mice further 
substantiated the role of SP in modulating COX-2 expression, whereby burn-injured 
PPT-A
-/-
 mice revealed significantly lowered lung COX-2 levels, however, upon 
administration of exogenous SP, the COX-2 levels were again elevated as anticipated 
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(Fig. 6.8A). More significantly, treatment with PD98059 in burn-injured PPT-A
-/-
 mice 
injected with SP markedly suppressed COX-2 expression levels.             
 
6.3.8 Increased SP-NK1R signaling enhanced ERK1/2 activation after burn injury 
 
Next, we verified the effect of SP-NK1R signaling on ERK1/2 phosphorylation. Our 
results show that ERK1/2 had undergone significant phosphorylation after burn in WT 
mice (Fig. 6.9A). This was abrogated in burn-injured WT mice administered with 
L703606 and PD98059 and in burn-injured PPT-A
-/-
 mice. The phosphorylation levels of 
ERK1/2 was restored in burn-injured PPT-A
-/-
 mice injected with SP and again reduced 
when burn-injured PPT-A
-/-
 mice injected with SP were treated with PD98059 (Fig. 6.9A). 
Therefore, these data clearly show that SP-NK1R signaling occurs upstream of ERK1/2 
and its inhibition significantly suppresses the activation of ERK1/2 which leads further to 
activation of downstream COX-2 expression.         
 
 
6.3.9 Effect of SP-NK1R signaling and ERK1/2 pathway on IκBα phosphorylation 
and degradation levels and activity of NF-κB after burn injury  
 
 
The phosphorylation, ubiquitination and subsequent proteolytic degradation of the 
inhibitor IκBα protein results in the release of NF-κB, the activated form consisting 
mainly of a heterodimer of p65 and p50, which consequently translocates to the nucleus, 
where it initiates the transcription of numerous inflammatory proteins (Barnes and Karin, 
1997). Therefore, we analyzed the activation levels of IκBα and NF-κB after burn injury. 
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Pre-treatment with L703606 in burn-injured WT mice drastically reduced the pulmonary 
levels of phospho-IκBα compared to the heightened levels detected in untreated burn-
injured WT mice (Fig. 6.10A). Furthermore, this reduction was consistent in burn-injured 
WT mice pre-treated with PD98059 and in burn-injured PPT-A
-/-
 mice. In contrast, the 
phospho-IκBα levels burn-injured PPT-A-/- mice injected with SP were again amplified; 
while these levels were suppressed upon pre-treatment with PD98059 (Fig. 6.10A). 
Assessment of the degradation of IκBα displayed a significant reduction in IκBα levels 
after burn in WT mice and in burn-injured PPT-A
-/-
 mice injected with SP, whereas the 
content of IκBα levels observed in all other groups where significantly higher (Fig. 
6.10B).        
 
 
The DNA-binding activity of nuclear NF-κB in the lungs of burn-injured WT mice were 
markedly enhanced compared to sham-injured WT mice, burn-injured WT mice treated 
with L703606 and PD98059, and in burn-injured PPT-A
-/-
 mice (Fig. 6.11A). Exogenous 
administration of SP to burn-injured PPT-A
-/-
 mice amplified the activation of NF-κB 
while pretreatment with PD98059, significantly disrupted the activity level of NF-κB in 
the lungs after burn (Fig. 6.11A). Next, to ascertain if COX-2 is up-regulated by NF-κB 
after burn, we administered Bay 11-7082 to mice, a specific inhibitor of NF-κB (Pierce et 
al., 1997), at 20mg/kg, i.p., 30min before burn injury, followed by measurement of COX-
2 activity levels at 2h post burn. Both burn-injured WT mice and burn-injured PPT-A
-/-
 
mice injected with SP showed increased levels of lung COX-2 activity at 2h post burn 
(Fig. 6.11B). However, pre-treatment with Bay 11-7082 showed significantly reduced 




injected with SP (Fig. 6.11B). Taken together, our findings demonstrate that SP-NK1R 
signaling contributes significantly in regulating the ERK-NF-κB dependent signal 
transduction pathway in a mouse model of burn-induced ALI.  
 
 




Defining the molecular mechanisms by which endogenous pulmonary inflammatory 
mediators initiate signal transduction pathways is of critical importance in elucidating the 
pathogenesis of ALI and ARDS. Numerous studies provide evidence which indicate that 
SP and NK1R are major pro-inflammatory mediators of lung diseases (Groneberg et al., 
2006; O'Connor et al., 2004). At the same time, a large body of evidence has accumulated 
after decades of research to show that COX-2 and PGE2 play pivotal roles in respiratory 
diseases such as ALI, chronic obstructive pulmonary disease, pulmonary fibrosis and 
lung cancer (Carpagnano et al., 2009; Chen et al., 2008; Fukunaga et al., 2005; Hinz and 
Brune, 2002; Lappi-Blanco et al., 2006; Park and Christman, 2006). Some studies have 
evidences which indicate that COX-2 and PGE2 might be associated with SP related 
inflammatory responses. For example, studies have shown SP to incite COX-2 and PGE2 
expression via JAK-STAT pathway in human colonic epithelial cells (Koon et al., 2006), 
and via MAP kinase pathway in human umbilical vein endothelial cells (Gallicchio et al., 
2006). SP was also shown to induce COX-2 expression and NF-κB activation in human 
polymorphonuclear leukocytes (Gallicchio et al., 2009). Furthermore, SP stimulated 
PGE2 via NK1R in isolated rat intrapulmonary bronchi and trachea preparations 
(Devillier et al., 1992; Szarek et al., 1998), and via PGE2 receptor subtype 2 in murine 
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tracheal preparations (Fortner et al., 2001). However, the interaction(s) between SP, 
COX-2 and PGE2 in burn-induced remote ALI is not known. Here, we report for the first 
time, the signal transduction pathway following SP-NK1R coupling which activates the 
ERK-NF-κB pathway, leading to subsequent COX-2 up-regulation and PGEM 
production, which then contributes to significant elevations in pulmonary pro-
inflammatory cytokines, chemokines, neutrophils and exacerbated ALI following severe 





 mice injected with exogenous SP supports these conclusions.  
 
Results of our time course studies showed that biosynthesis of SP and COX-2 expression 
levels were both concomitantly increased early after burn injury. As early as 30min post 
burn, the levels of SP and COX-2 expression were significantly elevated in WT mice 
compared to 0min post burn. Similarly the COX-2 activity levels were augmented, while 
ERK1/2 and IκBα were highly phosphorylated, along with concurrent observations of 
IκBα degradation. Interestingly, although, COX-2 activity was found to increase at 30min 
post-burn, while IκB phosphorylation occurred at 2h post-burn, it is possible that COX-2 
up-regulation can occur earlier as there are other pathways independent of IκB 
phosphorylation and NF-κB activation that can induce COX-2 levels. For example, the 
inducible expression of COX-2 is known to be up-regulated by numerous cytokines, 
growth factors and transcription factors (Krakauer, 2004; Wu, 1996). Hence, these 
proteins may contribute to the increased COX-2 expression levels at the earlier time point. 
Nevertheless, together, the occurrence of SP, COX-2, ERK1/2 and IκBα levels correlated 
well and remained highly up-regulated or activated in lungs for up to 8h post burn. 
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Thereby, these data suggest that the overproduction of SP and COX-2 levels after severe 
local burn injury is not a temporal early rise but are constantly maintained in lung cells 
for at least up to 8h post burn.  
 
The usage of L703606, a specific NK1R antagonist, in our study determined that SP 
signaled via NK1R, a G-protein coupled receptor (GPCR), to lead to the activation of 
COX-2, which then resulted in increased ALI, cytokines and chemokines production. 
Furthermore, usage of PD98059, a selective inhibitor of MEK-1, which is the upstream 
kinase of ERK1/2, directly ascertained the downstream involvement of ERK1/2 in SP-
NK1R mediated signaling in the lungs following burn injury. Pretreatment with PD98059 
in burn-injured WT mice and burn-injured PPT-A
-/-
 mice injected with exogenous SP 
consistently resulted in inhibition of ERK1/2, IκBα phosphorylation and degradation and 
attenuated the over-activation of NF-κB. Additionally, lung COX-2 activity levels were 
significantly reduced with the administration of Bay 11-7082, a specific inhibitor of NF-
κB, in burn-injured WT mice and burn-injured PPT-A-/- mice injected with SP. Notably, 
although the exogenous dose of 0.12µg/kg SP administered to burn-injured PPT-A
-/-
 mice 
corresponded to physiological endogenous SP plasma concentration in normal mice as 
explained in chapter II, here, our results indicate that this dose of 0.12µg/kg SP was 
sufficient for the activation of ERK1/2 for a period of 2h after burn injury. Hence, once 
the exogenous SP administered to PPT-A
-/-
 mice is able to activate SP-NK1R signaling 
after burn injury, this may be sufficient to initiate a cascade of downstream ERK1/2 
signaling which then leads to the exacerbation of ALI. Together, these findings 
collectively show that SP-NK1R coupling initiates a straightforward involvement of 
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ERK-NF-κB signaling pathway to induce up-regulation of COX-2 expression and ALI 
following burn injury.  
 
To verify that SP can work in conjunction with other major mediators such as COX-2 to 
induce ALI, we used a selective inhibitor of COX-2, parecoxib, to assess the role of SP-
induced COX-2 expression in burn-injured mice. Data derived from burn-injured PPT-A
-
/-
 mice injected with exogenous SP showed exacerbated ALI compared to alleviated ALI 
in burn-injured PPT-A
-/-
 mice alone. Thereby, indicating that burn-induced ALI was 
specifically attributable to the pro-inflammatory effects of SP. However, upon treatment 
with parecoxib in burn-injured PPT-A
-/-
 mice injected with exogenous SP, the observed 
heightened ALI severity was attenuated. Thus, confirming that SP has the ability to signal 
via COX-2 to instigate ALI after burn. Additionally, pulmonary cytokines and 
chemokines data from burn-injured PPT-A
-/-
 mice injected with exogenous SP and 
subsequently treated with or without parecoxib revealed that SP can regulate IL-1β, TNF-
α, IL-6, MIP-2 and MIP-1α levels via COX-2.  
 
It is known that more than 90% of circulating PGE2 is rapidly catabolized to inactive 
forms on the first pass in the lungs (Ivanov et al., 2003; Piper et al., 1970; Wyllie et al., 
1969). Therefore, studies have used the measurement of PGEM as a common alternative 
to indicate the levels of PGE2 (Bothwell et al., 1982; Duffield-Lillico et al., 2009; 
Granstrom et al., 1980; Gross et al., 2005; Maclouf et al., 1987). Significantly high levels 
of PGEM in the lungs were detected in burn-injured WT mice and in burn-injured PPT-A
-
/-
 mice injected with SP. The high levels of PGEM in these two groups of mice also 
 152 
corresponded with concurrent increases in COX-2 expression and ALI. Treatment with 
parecoxib and L703606 showed significantly reduced levels of PGEM in burn-injured 
WT mice, while PGEM levels were also lowered in burn-injured PPT-A
-/-
 mice injected 
with SP and subsequently treated with parecoxib. Consistently, the decreased levels of 
PGEM in these two groups of mice following parecoxib treatment showed suppressed 
COX-2 expression and alleviated ALI after burn. Therefore, these results may indicate 
that SP-NK1R signaling induces COX-2 expression which leads to PGE2 secretion and 
exacerbation of ALI. Also, it is interesting to note that the alterations in PGEM levels 
after burn may not only be due to the increase in production of PGE2 via the enzymatic 
actions of COX-2 after burn but also possibly due to a drop in PGE2 clearance and 
degradation by the lungs. Given that after burn injury, the lungs become severely injured, 
hence, this may not only affect respiratory function but also lead to the disruption of 
crucial metabolic activities such as the metabolism of PGE2. As such, excessive PGE2 
may accumulate to elicit pain, vasodilation, edema and immune dysfunction. 
 
In conclusion, our results show for the first time that SP regulates pulmonary 
inflammatory responses following severe local burn injury via the signaling transduction 
pathway involving: NK1R-ERK1/2-IκBα-NF-κB-COX-2 pathway which induces a 
marked rise in pulmonary PGEM levels that are indicative of increased PGE2 levels. 
Together, the overproduction of SP and COX-2 subsequently resulted in significantly 
exacerbated ALI after burn. Therefore, this study may contribute to a better 
understanding of the precise mechanisms initiated by SP in the pathophysiology of 















Figure 6.1 Time course study of SP levels in lung after burn injury. (A) SP levels in 
lung of WT mice were measured by ELISA at 0min, 30min, 1h, 2h, 4h and 8h after burn 






















































































































































































































































Figure 6.2 Time course study of COX-2 expression and activity in lungs after burn 
injury. (A) Western blot results showing COX-2 expression and (B) COX-2 activity 
levels in lung of WT mice at 0min, 30min, 1h, 2h, 4h and 8h after burn injury. Results 
shown are the mean values ± SEM (n = 4 mice per group for COX-2 expression levels, 




















































































Figure 6.3 Dose dependent effect of parecoxib on lung neutrophil infiltration at 2h 
post burn in WT mice. (A) MPO activity at 2h after sham or burn injury in the lungs of 
WT mice treated with 0, 5, 10, 20 and 30mg/kg parecoxib, i.v., administered 20min post 

































































































































































































































































































































































































































Figure 6.4 Inhibition of SP-NK1R signaling and COX-2 expression markedly 
reduced lung neutrophil infiltration and alleviated ALI after burn injury. (A) MPO 
activity and (B) histopathological evaluation (H&E staining) of PMN infiltration and 




 mice injected with SP (0.12µg/kg, 
i.v.) or vehicle (saline) immediately after sham or burn injury. In some WT mice, 
L703606 (12mg/kg, i.p., 1h before sham or burn injury) or parecoxib (30mg/kg, i.v., 
20min post burn) was administered. PPT-A
-/-
 mice injected with SP were also 
subsequently administered parecoxib (30mg/kg, i.v., 20min post burn). Results shown are 
the mean values ± SEM (n = 4-6 mice per group for MPO activity). *, p<0.05; **, p<0.01. 
Histology lung sections include: sham + saline (WT) (B1), sham + L703606 (WT) (B2), 
sham + parecoxib (WT) (B3), burn + saline (WT) (B4), burn + L703606 (WT) (B5), burn 
+ parecoxib (WT) (B6), sham + saline (PPT-A
-/-
) (B7), sham + SP (PPT-A
-/-
) (B8), sham 
+ SP + parecoxib (PPT-A
-/-
) (B9), burn + saline (PPT-A
-/-
) (B10), burn + SP (PPT-A
-/-
) 
(B11), burn + SP + parecoxib (PPT-A
-/-
) (B12). (n = 6-8 mice per group for histological 
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Figure 6.5 Significant reductions in pulmonary cytokines and chemokines after 
administration of L703606 and parecoxib after burn. Levels of IL-1β (A), IL-6 (B), 
TNF-α (C), MIP-2 (D) and MIP-1α (E) at 2h in lung of WT, PPT-A-/-, and PPT-A-/- mice 
injected with SP (0.12µg/kg, i.v.) or vehicle (saline) immediately after sham or burn 
injury. In some WT mice, L703606 (12mg/kg, i.p., 1h before sham or burn injury) or 
parecoxib (30mg/kg, i.v., 20min post burn) was administered. PPT-A
-/-
 mice injected with 
SP were also subsequently administered parecoxib (30mg/kg, i.v., 20min post burn). 
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Figure 6.6 Elevation in lung PGEM levels upon activation of SP-NK1R signaling 
and up-regulation of COX-2 expression following burn injury. (A) Levels of PGEM 




 mice injected with SP 
(0.12µg/kg, i.v.) or vehicle (saline) immediately after sham or burn injury. In some WT 
mice, L703606 (12mg/kg, i.p., 1h before sham or burn injury) or parecoxib (30mg/kg, i.v., 
20min post burn) was administered. PPT-A
-/-
 mice injected with SP were also 
subsequently administered parecoxib (30mg/kg, i.v., 20min post burn). Results shown are 



































































































































































































































































































































































































Figure 6.7 Time course study of ERK1/2 activation, phosphorylation and 
degradation of IκBα levels after burn injury. (A) phospho-ERK, (B) phospho-IκBα, 
and (C) IκBα expression levels, measured by western blot, in lung of WT mice at 0min, 








































































































Figure 6.8 Activation of SP-NK1R signaling and ERK1/2 pathway leads to increased 
COX-2 levels after burn injury. (A) Western blot results showing COX-2 expression 




 mice injected with SP (0.12µg/kg, i.v.) 
or vehicle (saline) immediately after sham or burn injury. In some WT or PPT-A
-/-
 mice 
injected with SP, L703606 (12mg/kg, i.p.) or PD98059 (10mg/kg, i.p.) was administered 
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Figure 6.9 SP-NK1R signaling induces the activation of ERK1/2 pathway following 





 mice injected with SP (0.12µg/kg, i.v.) or vehicle (saline) 
immediately after sham or burn injury. In some WT or PPT-A
-/-
 mice injected with SP, 
L703606 (12mg/kg, i.p.) or PD98059 (10mg/kg, i.p.) was administered 1h before sham or 







Burn           
+       
L703606 





































Sham + SP Burn +
saline










































































































































Burn           
+       
L703606 








































Sham + SP Burn +
saline































































































































Figure 6.10 SP-NK1R signaling and ERK1/2 pathway incites phosphorylation and 
degradation of IκBα levels after burn injury. (A) phospho-IκBα and (B) IκBα 





mice injected with SP (0.12µg/kg, i.v.) or vehicle (saline) immediately after sham or burn 
injury. In some WT or PPT-A
-/-
 mice injected with SP, L703606 (12mg/kg, i.p.) or 
PD98059 (10mg/kg, i.p.) was administered 1h before sham or burn injury. (n = 4 mice 
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Figure 6.11 Effect of SP-NK1R signaling and ERK1/2 pathway on NF-κB activation 
following burn injury. (A) NF-κB activation levels, measured by ELISA and (B) COX-




 mice injected with SP 
(0.12µg/kg, i.v.) or vehicle (saline) immediately after sham or burn injury. In some WT 
or PPT-A
-/-
 mice injected with SP, L703606 (12mg/kg, i.p.), PD98059 (10mg/kg, i.p.) or 
Bay 11-7082 (20mg/kg, i.p.) or vehicle, was administered 1h, 1h and 30min before burn 







Sham +  
saline   
Burn +  





Sham +    

















































































































Burn +  
saline +
vehicle
Burn +  





   Sham +     
SP + 
vehicle
Sham +      





   Burn +      
SP +   
vehicle
Burn +      























































Burn injury accompanied with severe ALI and respiratory dysfunction is a common 
clinical disorder in hospitals associated with high morbidity and mortality. However, the 
early triggers of remote ALI after severe local burn injury remains poorly understood. 
Therefore, defining the endogenous triggers that initiate and further mediate the early 
onset of systemic inflammation that leads to remote ALI represents an important goal, 
with immediate diagnostic, prognostic and therapeutic significance.  
 
There is accumulating evidence that neuropeptides and their receptors are essential 
mediators of inflammation. The activation of peripheral sensory innervation and 
neurogenic inflammatory events has been demonstrated to lead to the development and 
progression of multiple inflammatory diseases (Groneberg et al., 2006; O'Connor et al., 
2004). This phenomenon termed, „neurogenic inflammation‟, refers to inflammatory 
responses which results from the release of molecules from primary sensory nerve fibers 
(Akazawa et al., 2009). The neuropeptide, SP, for instance, has been well established to 
exert an extensive range of pro-inflammatory neural effects in vitro and in vivo, 
modulating many immune and non immune effector cell types (Carolan and Casale, 
1993; Harrison and Geppetti, 2001). Studies have also shown that SP via activation of 
NK1R mediates direct ALI and increased vascular permeability after cigarette (De Swert 
et al., 2009), oil (Li et al., 2008), and fire (Wong et al., 2004) smoke exposure. However, 
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the role of SP in instigating indirect and remote ALI after severe local burn injury, even 
in the absence of inhalational injury has not yet been investigated. Therefore, in the 
present study, we investigated the role of SP in a mouse model of burn-induced ALI.  
 
The major findings in our study show that male Balb/c mice subjected to 30% total body 
surface area full thickness exhibited significantly increased endogenous SP production in 
WT mice, and biological activity of SP-NK1R signaling. The enhanced SP production 
further resulted in significant elevation of pro-inflammatory cytokines, chemokines, 
endothelial adhesion molecules and cells counts of neutrophils, monocytes, and 
lymphocytes in the circulation; concurrent with disruption of pulmonary permeability 
barrier, excessive neutrophil infiltration and severe ALI. Additionally, decreased neutral 
endopeptidase and elevated matrix metalloproteinase-9 were evident. Notably, disruption 
of respiratory function further demonstrated a critical role of SP in lungs after burn injury. 
More importantly, these effects were significantly attenuated upon administration of 
L703606, a specific NK1R antagonist and in PPT-A gene deficient mice, which encodes 
for SP; while exogenous administration of SP to PPT-A
-/- 
mice restored the inflammatory 
response and ALI. Additionally, administration of SP analogue peptide in burn-injured 
WT or PPT-A
-/- 
mice failed to aggravate ALI, further verifying the pro-inflammatory role 
of SP.  
 
 
In the next part of this study, we investigated the molecular mechanisms by which SP 
induces remote ALI following severe local burn injury. Our results indicate that SP can 
work in conjunction with other important inflammatory mediators, such as COX-2, to 
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incite severe ALI after burn. Specifically, we show that SP acts via NK1R-ERK1/2-
NFκB-COX-2 pathway to induce significant up-regulation of PGEM which may further 
contribute to ALI following severe local burn injury. Furthermore, pharmacological 
blockade by administration of L703606 and PD98059 in WT mice and treatment of PPT-
A
-/- 
mice injected with exogenous SP with parecoxib or PD98059, resulted in significant 
reductions of lung COX-2, PGEM levels and attenuation of severe ALI after burn. 
Thereby, indicating that SP-NK1R signaling is an important regulator of inflammation 
after burn which also significantly influences the activity of COX-2.  
 
In conclusion, we provide for the first time, compelling evidence of the multiple roles of 
SP in instigating heightened inflammatory responses that contribute to the 
pathophysiology of remote ALI and disruption of breathing function, early after severe 
local burn injury. More importantly, our findings also indicate that the inhibition or 
absence of a single endogenous factor, SP, provides early protection against burn-induced 
ALI. Taken together, an in-depth study of SP and its multiple roles in up-regulating 
inflammatory pathways, signaling molecules and other prominent mediators of 
inflammation such as COX-2 and PGE2 may provide approaches for new forms of 
therapeutic interventions for the treatment and prevention of an acute pulmonary 
inflammatory cascade following severe injury in critically ill patients. A summary of the 












In summary, the important contributions of this study have addressed previously 
unknown areas. Here, our work presents for the first time substantial evidences of:  
 
 The early ability of SP to incite remote ALI and lung function disruption after 
severe local burn injury  
 SP working via other important inflammatory mediators, such as COX-2 to 
induce ALI after burn  
 the mechanism by which SP acts to induce ALI after burn 
 
Thereby, results of this study may highlight potential novel approaches, useful for the 
development of new treatments targeted at resolving the early inflammatory responses in 
critically burn-injured patients. By doing so, preventing the onset of early ALI will prove 
to have more practical benefit to the patient than efforts to treat ARDS once it has ensued. 
 
Nevertheless, much more research is required to fully elucidate the complex interactions 
of inflammatory molecules such as SP in the multifaceted pathophysiology of burn injury. 
Thereby, it is important to understand the simultaneous responses of various systems in 
response to SP after burn injury. For example, the intricate crosstalk of SP with the 
immune system could be examined by looking at the effect of SP binding to NK1R 
present on T cells, macrophages, neutrophils, and monocytes, which are important for 
understanding how the nervous system influences the immune response after burn injury. 
In this case, bone marrow derived chimeras could be used to determine the importance of 
SP-NK1R dependent signaling on the bone marrow derived cells in contributing to the 
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pathophysiology of burn injury. Futhermore, investigations on the role of SP in the 
cardiovascular pathology after burn would be an important area as heart failure is a major 
component of mortality in burn patients. For instance, studies on the responses of 
parenchymal cells of the cardiovascular system could be investigated.Understanding the 
interplay between the respiratory, cardiovascular and immune systems would help to 
understand how early interventions can be developed for the early treatment of patients 
with severe burns. More efforts may also be made to investigate candidate signaling 
molecules in inflammatory pathways that can lead to the initiation of ALI such as G-
coupled receptor associated proteins (e.g. Gαq and Gαs); upstream kinases that mediate 
the ERK1/2-NFκB pathway including protein kinases, phospholipases, small GTPases 
and calcium; other members of the MAPK family such as p38 MAPKs and JNK/SAPK 
family and other potential pathways underlying the pro-inflammatory effects of SP after 
burn injury. For instance, one interesting and potential pathway which could be examined 
is the role a more recent and novel protein family, the inflammasomes, in burn injury. 
Inflammasomes are muti-protein complexes that trigger the maturation of pro-
inflammatory cytokines like IL-1β to engage innate immune responses (Schroder and 
Tschopp, 2010). Studies have shown that the inflammasome, Nlrp3, mediates the 
development of sterile inflammatory responses (Iyer et al., 2009; Yamasaki et al., 2009). 
Furthermore, SP has been shown to activate inflammasomes that express NK1R in a rat 
fracture model (Li et al., 2009). However, to our understanding, it appears that the roles 
of SP and inflammasomes have not been investigated after burn. Finally, investigations in 
large animals and human patients would be important to further verify results based on 





























Figure 7.1 Flowchart summarizing the pro-inflammatory effects of SP in ALI 
following severe local burn injury. Burn injury results in increased PPT-A gene 
expression, an overproduction of endogenous SP and elevated NK1R expression levels, 
along with a decrease in NEP levels. Together, these contribute to the increased 
activatation of SP-NK1R signaling which stimulates the phosphorylation of ERK1/2, 
leading to the phosphorylation and degradation of IκBα as well as the activation of NF-
κB. As such, COX-2 and PGEM levels are augmented. SP-NK1R signaling also leads to 
increased cytokines, chemokines, MMP-9, adhesion molecules, neutrophil, monocyte and 
lymphocyte cells in blood, and depletion of platelet numbers. The accumulation of all 
these events, leads to pulmonary vascular leakage, edema, alveolar congestion and ALI, 
which in turn disrupts lung function. Usage of L703606, PD98059, Bay 11-7082 and 
parecoxib, which are specific NK1R, MEK-1, NF-κB and COX-2 antagonists 
respectively confirm these signaling events.  indicates inhibition.  
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